var title_f29_1_29712="PDA arteriogram III";
var content_f29_1_29712=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61946&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61946&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Patent ductus arteriosus arteriogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 407px; height: 404px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A lateral angiogram of the transverse aortic arch and descending aorta (Ao) demonstrating a patent ductus arteriosus (arrow) with left to right shunt of contrast into the main pulmonary artery (MPA).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin Hill, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_1_29712=[""].join("\n");
var outline_f29_1_29712=null;
var title_f29_1_29713="Volvulus corkscrew";
var content_f29_1_29713=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75419&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75419&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 481px\">",
"   <div class=\"ttl\">",
"    Volvulus corkscrew",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 461px; height: 499px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This upper gastrointestinal contrast study demonstrates the corkscrew appearance of the twisted small bowel in volvulus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Carlo Buonomo, MD, Children's Hospital-Boston. Copyright &copy; Carlo Buonomo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_1_29713=[""].join("\n");
var outline_f29_1_29713=null;
var title_f29_1_29714="Hydroxypropyl cellulose: Drug information";
var content_f29_1_29714=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Hydroxypropyl cellulose: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?17/57/18323?source=see_link\">",
"    see \"Hydroxypropyl cellulose: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F180919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lacrisert&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F180920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Lacrisert&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F180928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Ophthalmic Agent, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F180921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ocular lubricant: Ophthalmic: Apply once daily into the inferior cul-de-sac beneath the base of tarsus, not in apposition to the cornea nor beneath the eyelid at the level of the tarsal plate",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F180922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F180913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Insert, ophthalmic [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lacrisert&reg;: 5 mg (60s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F180906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F180914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dry eyes (moderate-to-severe)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F180926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined: Ocular: Blurred vision, edema of the eyelids, local irritation",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6220906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13888220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hydroxypropyl cellulose is physiologically inert and is not metabolized. It was not absorbed following oral administration in animal studies. Systemic absorption would be required in order for hydroxypropyl cellulose to cross the placenta and reach the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F180916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      INST",
"     </b>",
"     (Lacrisert Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (60): $386.83",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F180917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Lacrisert (AU, FI, FR, NL, SE, TW)",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8978 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-6A22C7A760-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_1_29714=[""].join("\n");
var outline_f29_1_29714=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180919\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180920\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180928\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180921\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180922\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180913\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180906\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180914\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180926\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299492\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6220906\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13888220\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180916\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180917\">",
"      International Brand Names",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8978\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8978|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/57/18323?source=related_link\">",
"      Hydroxypropyl cellulose: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_1_29715="Int and ext hemorrhoids PI";
var content_f29_1_29715=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F80650%7EPI%2F51116&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F80650%7EPI%2F51116&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hemorrhoids",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 381px; height: 338px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hemorrhoids that are hidden inside the rectum are called \"internal\" hemorrhoids. You cannot see them, but they can cause symptoms. Hemorrhoids that you can see or feel are called \"external\" hemorrhoids.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    External hemorrhoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 404px; height: 448px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure shows what an external hemorrhoid looks like.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_1_29715=[""].join("\n");
var outline_f29_1_29715=null;
var title_f29_1_29716="Ligasure device";
var content_f29_1_29716=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F66593&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F66593&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    LigaSure&trade; device",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 346px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    LigaSure&trade; device being used to divide ileocolic artery in laparoscopic colectomy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jon Gould, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_1_29716=[""].join("\n");
var outline_f29_1_29716=null;
var title_f29_1_29717="Human papillomavirus bivalent (types 16, 18) recombinant vaccine: Pediatric drug information";
var content_f29_1_29717=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Human papillomavirus bivalent (types 16, 18) recombinant vaccine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?39/46/40677?source=see_link\">",
"    see \"Human papillomavirus bivalent (types 16, 18) recombinant vaccine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?4/9/4242?source=see_link\">",
"    see \"Human papillomavirus bivalent (types 16, 18) recombinant vaccine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9514407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cervarix&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F10135562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cervarix&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F9904146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vaccine, Inactivated (Viral)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F9904155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/46/40677?source=see_link\">",
"      see \"Human papillomavirus bivalent (types 16, 18) recombinant vaccine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Immunization:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Female: Children (preadolescent) &ge;9 years, Adolescents, and Adults &le;25 years: Initial dose: I.M.: 0.5 mL followed by a second dose 1 month after first dose; third dose 6 months after first dose (immunization with HPV vaccine is usually initiated at 11-12 years; optimally, vaccination should be completed prior to onset of sexual activity)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     CDC recommended immunization schedule: Administer first dose to females at age 11-12 years; begin series in females aged 13-25 years if not previously vaccinated. Minimum interval between the first and second dose of vaccine is 4 weeks; minimum interval between the second and third dose of vaccine is 12 weeks; minimum interval between first and third dose of the vaccine is 24 weeks. If the vaccine series is interrupted and only one dose was given, administer the second dose as soon as possible and give the third dose &ge;12 weeks later. If the vaccine series is interrupted and the first two doses were given, administer the third dose as soon as possible. If the dose is given in an interval shorter than recommended, the dose should be repeated. The HPV vaccine series should be completed with the same product whenever possible.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9518301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, suspension [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cervarix&reg;: HPV 16 L1 protein 20 mcg and HPV 18 L1 protein 20 mcg per 0.5 mL (0.5 mL [DSC]) [contains aluminum; manufactured using",
"     <i>",
"      Trichoplusia ni",
"     </i>",
"     (insect cells)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cervarix&reg;: HPV 16 L1 protein 20 mcg and HPV 18 L1 protein 20 mcg per 0.5 mL (0.5 mL) [contains aluminum, natural rubber/natural latex in prefilled syringe; manufactured using",
"     <i>",
"      Trichoplusia ni",
"     </i>",
"     (insect cells)]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9559847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9904156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.M.: Shake suspension well prior to use; do not use suspension if it is discolored or contains particulate matter; should be a homogenous, turbid, white suspension. Do not dilute or mix with other vaccines. Administer I.M. into the deltoid region of the upper arm;",
"     <b>",
"      not for I.V., intradermal, or SubQ administration",
"     </b>",
"     . Adolescents and adults should be vaccinated while seated or lying down. U.S. law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, and the administering person&rsquo;s name, title and address be entered into the patient&rsquo;s permanent medical record.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F9904152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Store under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze; discard if frozen. May develop a fine, white deposit with a clear, colorless supernatant during storage (not a sign of deterioration).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9904147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prevention of cervical cancer and cervical intraepithelial neoplasia with or without cervical adenocarcinoma",
"     <i>",
"      in situ",
"     </i>",
"     caused by Human Papillomavirus (HPV) types 16 and 18 (FDA approved in girls &ge;9 years and women &le;25 years of age)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination for females 11-12 years of age; catch-up vaccination is recommended for females 13-25 years of age (CDC, 2010). Vaccination is also recommended for immunocompromised females through 26 years of age who were not previously vaccinated when they were younger. Although not specifically recommended for their profession, female healthcare providers within the recommended age groups should also receive the HPV vaccine.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9518289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Papillomavirus vaccine types 16, 18 (Cervarix&reg;) may be confused with Papillomavirus vaccine types 6, 11, 16, 18 (Gardasil&reg;)",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cervarix&reg; may be confused with Cerebyx&reg;, CeleBREX&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F9559858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at",
"      <a href=\"https://vaers.hhs.gov/esub/index\" target=\"_blank\">",
"       https://vaers.hhs.gov/esub/index",
"      </a>",
"      .",
"     </b>",
"     In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Central nervous system: Fatigue",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reactions: Pain, pruritus, redness, swelling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Nasopharyngitis, pharyngitis, pharyngolaryngeal pain, upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Chlamydia infection, influenza, vaginal infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Allergic reactions, anaphylactic/anaphylactoid reactions, angioedema, erythema multiforme, lymphadenopathy, syncope (may be associated with tonic-clonic movements), vasovagal response",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9904149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to human papillomavirus vaccine or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F9904170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Immunization should be delayed during the course of an acute severe febrile illness; may administer to patients with mild acute illness (with or without fever). Use with caution in severely immunocompromised patients (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy, including high-dose corticosteroids); may have a reduced response to vaccination and vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval (CDC, 2011). In general, household and close contacts of persons with altered immunocompetence may receive all age-appropriate vaccines.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution in patients with bleeding disorders such as hemophilia or thrombocytopenia or patients on anticoagulant therapy, due to an increased risk for bleeding following I.M. administration. Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (CDC, 2011). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9904150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Immediate treatment for anaphylactic reactions should be available during vaccine use. There is no evidence that individuals exposed to or infected with HPV will be protected; those already infected with one or more HPV types were protected from disease in the remaining HPV types. Not for the treatment of active disease; does not protect against diseases caused by nonvaccine HPV types. Syncope has been reported with use of injectable vaccines and may be accompanied by transient visual disturbances, weakness, or tonic-clonic movements. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Avoid use of prefilled syringes in latex hypersensitive patients; tip cap and plunger contain latex and may cause an allergic reaction to occur. The single dose vial stopper does not contain latex.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9613147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cytarabine (Liposomal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9559848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9559849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Vaccination with papilloma virus vaccine is not recommended in pregnant women. In clinical trials, pregnancy testing was conducted prior to each vaccine administration and vaccination was discontinued if the woman was found to be pregnant; women were also instructed to avoid pregnancy for 2 months after receiving the vaccine. Pregnancies detected within 30 days prior or 45 days after vaccination had a higher rate of spontaneous abortions. A registry has been established for women exposed to Cervarix&reg; during pregnancy (888-452-9622).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;display:inline\">",
"     Administration of the vaccine in pregnancy is not recommended; until additional information is available, the vaccine series (or completion of the series) should be delayed until pregnancy is completed. Pregnancy testing is not required prior to administration of the vaccine (CDC, 2013).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9904157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Observe for syncope for 15 minutes following administration. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion. Adolescents and adults should be vaccinated while seated or lying down. Patient should continue to be screened for cervical cancer per current guidelines after vaccination series is completed.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9904153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Promotes immunity to human HPV types 16 and 18 by inducing the production of IgG neutralizing antibodies to the virus types",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F9904172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Peak seroconversion was observed 1 month following the last dose of vaccine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: Not well defined; &gt;5 years",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F9904225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/9/4242?source=see_link\">",
"      see \"Human papillomavirus bivalent (types 16, 18) recombinant vaccine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     This vaccine does not substitute for regular, routine cervical cancer screening; the vaccine is not intended for the treatment of active genital warts or cervical cancer. This vaccine should not be used in pregnant women. This vaccine may be given during a minor illness, such as a cold or low-grade fever. Three doses will be required for effective immunity. Inform prescriber immediately if difficulty breathing, chest pain, acute headache, rash, difficulty swallowing, or excessive pain/swelling at injection site occurs.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F9904158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Comparison of HPV vaccines: Cervarix&reg; and Gardasil&reg; are both vaccines formulated to protect against infection with the human papillomavirus. Both are inactive vaccines which contain proteins HPV16 L1 and HPV 18 L1, the cause of &gt;70% of invasive cervical cancer. The vaccines differ in that Gardasil&reg; also contains HPV 6 L1 and HPV 11 L1 proteins which protect against 75% to 90% of genital warts. The vaccines also differ in their preparation and adjuvants used. The viral proteins in Cervarix&reg; are prepared using",
"     <i>",
"      Trichoplusia ni",
"     </i>",
"     (insect cells) which are adsorbed onto an aluminum salt which is also combined with a monophosphoryl lipid. The viral proteins in Gardasil&reg; are prepared using",
"     <i>",
"      S. cerevisiae",
"     </i>",
"     (baker's yeast) which are then adsorbed onto an aluminum salt. Results from a short-term study (measurements obtained 1 month following the third vaccination in the series) have shown that the immune response to HPV 16 and HPV 18 may be greater with Cervarix&reg;; although the clinical significance of these differences is not known, local adverse events may also occur more frequently with this preparation. Both vaccines are effective and results from long-term studies are pending.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single visit, unless contraindications exist. If available, the use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and potential adverse events. If separate vaccines being used, evaluate product information regarding same syringe compatibility of vaccines. Separate needles and syringes should be used for each injection. The ACIP prefers each dose of specific vaccine in a series come from the same manufacturer if possible (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     For additional information, please refer to the following website:",
"     <a href=\"file://www.cdc.gov/vaccines/vpd-vac/\" target=\"_blank\">",
"      file://www.cdc.gov/vaccines/vpd-vac/",
"     </a>",
"     .",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      AAP Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, \"Febrile Seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(6):1281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/1/29717/abstract-text/18519501/pubmed\" id=\"18519501\" target=\"_blank\">",
"        18519501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Advisory Committee On Immunization Practices, &ldquo;Vaccines for Children Program, Vaccines to Prevent Human Papillomavirus (HPV) Infection,&rdquo; October 2009.  Available at",
"      <a href=\"file://www.cdc.gov/vaccines/programs/vfc/downloads/resolutions/1009hpv-508.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/vaccines/programs/vfc/downloads/resolutions/1009hpv-508.pdf",
"      </a>",
"      .",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Infectious Diseases, \"Recommended Childhood and Adolescent Immunization Schedules &minus; United States, 2009,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2009, 123(1):189-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/1/29717/abstract-text/19117881/pubmed\" id=\"19117881\" target=\"_blank\">",
"        19117881",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"General Recommendations on Immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2006, 55(RR-15):1-48. Available at:",
"      <a href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5515a1.htm\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5515a1.htm",
"      </a>",
"      .",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/1/29717/abstract-text/17136024/pubmed\" id=\"17136024\" target=\"_blank\">",
"        17136024",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Syncope After Vaccination-United States, January 2005-July 2007,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2008, 2;57(17):457-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/1/29717/abstract-text/18451756/pubmed\" id=\"18451756\" target=\"_blank\">",
"        18451756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Center for Immunization and Respiratory Diseases, \"General Recommendations on Immunization - Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/1/29717/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15566 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-5849588C53-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_1_29717=[""].join("\n");
var outline_f29_1_29717=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9514407\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10135562\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9904146\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9904155\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9518301\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559847\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9904156\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9904152\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9904147\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9518289\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559858\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9904149\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9904170\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9904150\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299821\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9613147\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559848\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559849\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9904157\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9904153\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9904172\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9904225\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9904158\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15566\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15566|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/46/40677?source=related_link\">",
"      Human papillomavirus bivalent (types 16, 18) recombinant vaccine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/9/4242?source=related_link\">",
"      Human papillomavirus bivalent (types 16, 18) recombinant vaccine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_1_29718="Splinting material";
var content_f29_1_29718=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F59847&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F59847&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 518px\">",
"   <div class=\"ttl\">",
"    Splinting material",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 498px; height: 513px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Common splinting materials include cotton padding (eg, Webril&reg;), plaster, and stockinette (A). Layers of plaster are placed between layers of padding (B). Padding between the skin and plaster must be thick enough to prevent excessive pressure and injury but thin enough to allow adequate immobilization. Usually four layers is sufficient. A stockinette may be placed over the splint (C and D).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard Derby, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_1_29718=[""].join("\n");
var outline_f29_1_29718=null;
var title_f29_1_29719="Well different beta catenin";
var content_f29_1_29719=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F72963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F72963&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Well differentiated (intestinal type) gastric adenocarcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Beta-catenin stain is prominent in the tumor cell membranes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_1_29719=[""].join("\n");
var outline_f29_1_29719=null;
var title_f29_1_29720="Nilotinib: Drug information";
var content_f29_1_29720=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nilotinib: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?18/9/18582?source=see_link\">",
"    see \"Nilotinib: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F5501066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tasigna&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F6860243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Tasigna&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F5501062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Tyrosine Kinase Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F5501140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Chronic myeloid leukemia (CML), Ph+, newly-diagnosed in chronic phase:",
"     </b>",
"     Oral: 300 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      CML, Ph+, resistant or intolerant in chronic or accelerated phase:",
"     </b>",
"     Oral: 400 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Gastrointestinal stromal tumor (GIST), refractory (unlabeled use):",
"     </b>",
"     Oral: 400 mg twice daily (Montemurro, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Dosage adjustment for concomitant CYP3A4 inhibitors/inducers:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      CYP3A4 inhibitors:",
"     </i>",
"     Avoid the concomitant use of a strong CYP3A4 inhibitor with nilotinib. If a strong CYP3A4 inhibitor is required, interruption of nilotinib treatment is recommended; if therapy cannot be interrupted and concurrent use cannot be avoided, consider reducing the nilotinib dose to 300 mg once daily in patients with resistant or intolerant Ph+ CML (chronic or accelerated phase) or to 200 mg once daily in newly-diagnosed chronic phase Ph+ CML, with careful monitoring, especially of the QT interval. When a strong CYP3A4 inhibitor is discontinued, allow a washout period prior to adjusting nilotinib dose upward.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      CYP3A4 inducers:",
"     </i>",
"     Avoid the concomitant use of a strong CYP3A4 inducer with nilotinib  (based on pharmacokinetic parameters, an increased nilotinib dose is not likely to compensate for decreased exposure).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F5501141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F5501142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-top:0em;display:inline\">",
"     Not studied in patients with serum creatinine &gt;1.5 times ULN, however, nilotinib and its metabolites have minimal renal excretion; dosage adjustments for renal dysfunction may not be necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F5501143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosage adjustment for impairment at treatment initiation (if possible, consider alternative therapies first); recommendations vary by indication.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Newly-diagnosed Ph+ CML in chronic phase:",
"     </i>",
"     Mild-to-severe impairment (Child-Pugh class A, B, or C): Initial: 200 mg twice daily; may increase to 300 mg twice daily based on patient tolerability",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Resistant or intolerant Ph+ CML in chronic or accelerated phase:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Mild-to-moderate impairment (Child-Pugh class A or B): Initial: 300 mg twice daily; may increase to 400 mg twice daily based on patient tolerability",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Severe impairment (Child-Pugh class C): Initial: 200 mg twice daily; may increase to 300 mg twice daily and then further increased to 400 mg twice daily based on patient tolerability",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      For hepatotoxicity during treatment:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     If bilirubin &gt;3 times ULN (&ge;grade 3): Withhold treatment, monitor bilirubin, resume treatment at 400 mg once daily when bilirubin returns to &le;1.5 times ULN (&le;grade 1)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     If ALT or AST &gt;5 times ULN (&ge;grade 3): Withhold treatment, monitor transaminases, resume treatment at 400 mg once daily when ALT or AST returns to &le;2.5 times ULN (&le;grade 1)",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F5501144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Dosage adjustment for hematologic toxicity:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     ANC &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and/or platelets &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Withhold treatment, monitor blood counts",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     If ANC &gt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and platelets &gt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     within 2 weeks: Resume at prior dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     If ANC &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and/or platelets &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     for &gt;2 weeks: Reduce dose to 400 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Dosage adjustment for nonhematologic toxicity:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Amylase or lipase &gt;2 times ULN (&ge;grade 3): Withhold treatment, monitor serum amylase or lipase, resume treatment at 400 mg once daily when lipase or amylase returns to &le;1.5 times ULN (&le;grade 1)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Lipase increases in conjunction with abdominal symptoms: Withhold treatment and consider diagnostics to exclude pancreatitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Clinically-significant moderate or severe nonhematologic toxicity: Withhold treatment, upon resolution of toxicity, resume at 400 mg once daily; may escalate back to initial dose (300 mg twice daily or 400 mg twice daily depending on indication) if clinically appropriate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Dosage adjustment for QT prolongation:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Repeat ECG ~7 days after any dosage adjustment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     QT",
"     <sub>",
"      c",
"     </sub>",
"     &gt;480 msec: Withhold treatment, monitor and correct potassium and magnesium levels; review concurrent medications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     If QT",
"     <sub>",
"      c",
"     </sub>",
"     F returns to &lt;450 msec and to within 20 msec of baseline within 2 weeks: Resume at prior dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     If QT",
"     <sub>",
"      c",
"     </sub>",
"     F returns to 450-480 msec after 2 weeks: Reduce dose to 400 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     If QT",
"     <sub>",
"      c",
"     </sub>",
"     F &gt;480 msec after dosage reduction to 400 mg once daily: Discontinue treatment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F5501178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tasigna&reg;: 150 mg, 200 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F5501060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7885624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at file://www.pharma.us.novartis.com/product/pi/pdf/tasigna_pmg.pdf, must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5501171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer twice daily doses ~12 hours apart. Administer on an empty stomach, at least 1 hour before or 2 hours after food. Capsules should be swallowed whole with water. If unable to swallow whole, may empty contents into 5 mL applesauce and administer within 15 minutes (do not save for later use). If a dose is missed, do not make up, resume with next scheduled dose.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F5501067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of newly-diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) in chronic phase; treatment of chronic and accelerated phase Ph+ CML refractory or intolerant to prior therapy (including imatinib)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F13892804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of refractory gastrointestinal stromal tumor (GIST)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5501055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Nilotinib may be confused with dasatinib, imatinib, nilutamide, ponatinib, SUNItinib,  vandetanib",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F5501103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Peripheral edema (8% to 15%), hypertension (10% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (20% to 35%), fatigue (21% to 32%), fever (11% to 28%), insomnia (7% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Rash (29% to 38%), pruritus (20% to 32%), alopecia (11% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypophosphatemia (grades 3/4: 5% to 17%), hyperglycemia (grades 3/4: 6% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (20% to 37%), vomiting (11% to 29%), diarrhea (14% to 28%), constipation (17% to 26%), lipase increased (1% to &ge;10%; grades 3/4: 7% to 18%), abdominal pain (12% to 17%), anorexia (12% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Neutropenia (grades 3/4: 12% to 42%; median duration: 15 days), thrombocytopenia (grades 3/4: 10% to 42%; median duration: 22 days), anemia (grades 3/4: 4% to 27%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Hyperbilirubinemia (&ge;10%; grades 3/4: 4% to 9%), ALT increased (&ge;10%; grades 3/4: 4%), AST increased (&ge;10%; grades 3/4: 1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (16% to 26%), limb pain (11% to 20%), myalgia (14% to 19%), back pain (14% to 17%), weakness (11% to 16%), bone pain (14% to 15%), muscle spasm (11% to 15%), musculoskeletal pain (11% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Cough (14% to 27%), nasopharyngitis (15% to 24%), dyspnea (9% to 15%), upper respiratory tract infection (&le;15%), oropharyngeal pain (7% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Night sweats (12% to 27%), flu-like syndrome (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Angina, arrhythmia (including AV block, atrial fibrillation, bradycardia, cardiac flutter, extrasystoles, and tachycardia), chest pain (including noncardiac), flushing, palpitation, QT interval prolonged",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness (10%), anxiety, depression, dysphonia, hypoesthesia, malaise, pain, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Dry skin (&gt;5% to &lt;10%), acne, bruising, dermatitis (including allergic and acneiform), eczema, erythema, folliculitis, hyperhidrosis, skin papilloma, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypokalemia (grades 3/4: &le;9%), hyponatremia (grades 3/4: &le;7%), hyperkalemia (grades 3/4: 2% to 6%), hypocalcemia (grades 3/4: &le;5%), albumin decreased (grades 3/4: &le;4%), diabetes mellitus, hypercalcemia, hypercholesterolemia, hyperlipidemia, hyperphosphatemia, hypomagnesemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Dyspepsia (4% to 10%), abdominal discomfort, abnormal taste, amylase increased, flatulence, pancreatitis, weight gain/loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Pollakuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Lymphopenia, neutropenic fever, pancytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Alkaline phosphatase increased (grades 3/4: &le;1%), GGT increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Paresthesia, peripheral neuropathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Eyelid edema (1%), conjunctivitis, dry eye, eye hemorrhage, periorbital edema, pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Pleural effusion (&le;1%), dyspnea (exertional), epistaxis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Abscess, amnesia, arteriosclerosis, arthritis, bronchitis, candidiasis, cardiac failure, cardiac murmur, cardiomegaly, cholestasis, chorioretinopathy, confusion, coronary artery disease, creatinine increased, cyanosis, dehydration, diplopia, dysuria, ejection fraction decreased, enterocolitis, eosinophilia, erectile dysfunction, erythema multiforme, erythema nodosum, exfoliative rash, gastric ulcer, gastroenteritis, gastrointestinal hemorrhage, gastrointestinal ulcer perforation, gout, gynecomastia, hearing impairment, hematoma, hemorrhagic shock, hepatitis, hepatomegaly, hepatotoxicity, herpes simplex infection, hiatal hernia, hyperemia (scleral, conjunctival, ocular), hyper-/hypothyroidism, hyperparathyroidism (secondary), hypersensitivity, hypertensive crisis, hyperuricemia, hypoglycemia, hypotension, interstitial lung disease, intracranial hemorrhage, lactic dehydrogenase increased, leukocytosis, loss of consciousness, MI, migraine, mouth ulceration, optic neuritis, oral papilloma, palmar-plantar erythrodysesthesia syndrome, papilledema, pericarditis, peripheral arterial occlusive disease, pleurisy, pneumonia, psoriasis, pulmonary edema, pulmonary hypertension, rectal hemorrhage, renal failure, restless leg syndrome (RLS), retroperitoneal hemorrhage, sepsis, sinusitis, skin atrophy, skin hyperpigmentation, skin hypertrophy, skin ulcer, stomatitis, subileus, sudden death, syncope, thrombocythemia, thrombocytosis, thrombosis, thyroiditis, tinea pedis, troponin increased, tumor lysis syndrome, ulcerative esophagitis, urinary tract infection, ventricular dysfunction, visual acuity decreased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F5501084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use in patients with hypokalemia, hypomagnesemia, or long QT syndrome",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindication (not in U.S. labeling):  Hypersensitivity to nilotinib or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5501085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: Reversible myelosuppression, including grades 3 and 4 thrombocytopenia, neutropenia and anemia may occur; may require dose reductions and/or treatment delay. Monitor blood counts.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte imbalance: Electrolyte abnormalities may occur during treatment, including hypophosphatemia, hyper-/hypokalemia, hypocalcemia and hyponatremia. Correct electrolyte abnormalities prior to treatment initiation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: May cause hepatotoxicity, including dose-limiting elevations in bilirubin, transaminases, and alkaline phosphatase; monitor liver function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; QT prolongation/sudden death:",
"     <b>",
"      [U.S. Boxed Warning]: May prolong the QT interval; sudden deaths have been reported. Use in patients with hypokalemia, hypomagnesemia, or long QT syndrome is contraindicated. Correct hypomagnesemia and hypokalemia prior to initiating therapy; monitor electrolytes periodically. Monitor ECG and QT",
"      <sub>",
"       c",
"      </sub>",
"      (baseline, at 7 days, with dose change, and periodically). Avoid the use of QT-prolonging agents and strong CYP3A4 inhibitors.",
"     </b>",
"     The sudden deaths reported appear to be related to dose-dependent ventricular repolarization abnormalities. Prolonged QT interval may result in torsade de pointes, which may cause syncope, seizure, and/or death. Patients with uncontrolled or significant cardiovascular disease were excluded from studies.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tumor lysis syndrome: Tumor lysis syndrome (TLS) has been reported in patients with resistant or intolerant CML; the majority of cases had malignant disease progression, high WBC counts, and/or dehydration. Maintain adequate hydration and treat high uric acid levels prior to nilotinib.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrectomy: Consider alternative therapy or a dosage increase (with more frequent monitoring) in patients with total gastrectomy (nilotinib exposure is reduced).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Dosage reduction is recommended in patients with hepatic impairment, along with close monitoring of QT interval. Nilotinib metabolism is primarily hepatic; exposure is increased in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pancreatitis: Use with caution in patients with a history of pancreatitis, may cause dose-limiting elevations of serum lipase and amylase; monitor. In patients with abdominal symptoms in conjunction with lipase increases, withhold treatment and consider diagnostics to exclude pancreatitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP3A4 inhibitors:",
"     <b>",
"      [U.S. Boxed Warning]: Avoid concurrent use with strong CYP3A4 inhibitors",
"     </b>",
"     (including grapefruit juice); interrupt nilotinib treatment if a strong CYP3A4 inhibitor is required; if coadministration cannot be avoided, consider nilotinib dose reductions. CYP3A4 inducers (including St John&rsquo;s wort) should also be avoided.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; QT-prolonging agents: Avoid concurrent use with antiarrhythmics and other drugs which may prolong QT interval; may increase the risk of potentially-fatal arrhythmias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lactose: Capsules contain lactose; do not use with galactose intolerance, severe lactase deficiency, or glucose-galactose malabsorption syndromes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate administration:",
"     <b>",
"      [U.S. Boxed Warning]: Administer on an empty stomach, at least 1 hour before and 2 hours after food.",
"     </b>",
"     Food increased the bioavailability/serum levels which may then prolong  QT",
"     <sub>",
"      c",
"     </sub>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F5501117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C8 (moderate), CYP2C9 (moderate), CYP2D6 (moderate), CYP3A4 (weak), P-glycoprotein, UGT1A1;",
"     <b>",
"      Induces",
"     </b>",
"     CYP2B6 (weak/moderate), CYP2C8 (weak/moderate), CYP2C9 (weak/moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F5501116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of Nilotinib. Management: Separate the administration of nilotinib and any antacid by several hours whenever possible in order to minimize the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inhibitors (Moderate) may decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     H2-Antagonists: May decrease the serum concentration of Nilotinib. Management: Separate the administration of nilotinib and the H2 receptor antagonist by several hours whenever possible in order to minimize the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebivolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May decrease the serum concentration of Nilotinib. Management: Avoid this combination when possible since separation of doses is not likely to be an adequate method of minimizing the interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F5501120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Grapefruit juice may result in increased concentrations of nilotinib and potentiate QT prolongation. Management: Avoid grapefruit juice.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: St John&rsquo;s wort may decrease nilotinib levels. Administration with grapefruit juice may result in increased concentrations of nilotinib and potentiate QT prolongation. Management: Avoid St John's wort and grapefruit juice.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F5501069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5501070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have demonstrated embryo-fetal toxicity and maternal toxicity. Women of childbearing potential should be advised to use effective contraception during treatment.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F5501082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5501083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     According to the manufacturer, the decision to discontinue breast-feeding during therapy or to discontinue nilotinib should take into account the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F5501123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The bioavailability of nilotinib is increased with food. Take on an empty stomach, at least 1 hour before or 2 hours after food.  Avoid grapefruit juice.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16321790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Tasigna Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (28): $2403.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (28): $2403.02",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5501173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential (every 2 weeks for first 2 months, then monthly); electrolytes (including potassium and magnesium; baseline and periodic); lipid profile (periodic), hepatic function (ALT/AST, bilirubin, alkaline phosphatase; baseline and monthly or as clinically indicated); serum lipase/amylase (baseline and monthly or as clinically indicated); bone marrow assessments; ECG and QT",
"     <sub>",
"      c",
"     </sub>",
"     (baseline, 7 days after treatment initiation or dosage adjustments, and periodically thereafter)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Thyroid function testing (Hamnvik, 2011):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Preexisting levothyroxine therapy: Obtain baseline TSH levels, then monitor every 4 weeks until levels and levothyroxine dose are stable, then monitor every 2 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Without pre-existing thyroid hormone replacement: TSH at baseline, then monthly for 4 months, then every 2-3 months",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Tasigna (AR, AT, AU, BE, BR, CH, CL, CN, CO, CZ, DE, DK, EE, FR, GB, GR, HK, HN, ID, IE, IL, IT, KP, MY, NL, NO, NZ, PH, PL, PT, RU, SE, SG, TH, TR, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F5501169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Selective tyrosine kinase inhibitor that targets BCR-ABL kinase, c-KIT and platelet derived growth factor receptor (PDGFR); does not have activity against the SRC family. Inhibits BCR-ABL mediated proliferation of leukemic cell lines by binding to the ATP-binding site of BCR-ABL and inhibiting tyrosine kinase activity. Nilotinib has activity in imatinib-resistant BCR-ABL kinase mutations.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F5501131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~98%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; oxidation and hydroxylation, via CYP3A4 to primarily inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Capsule: ~50% (when compared to oral solution with pH of 1.2-1.3); two 200 mg capsules sprinkled on applesauce was determined to be bioequivalent to two 200 mg intact capsules; bioavailability is increased 82% when administered 30 minutes after a high-fat meal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~15-17 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (93%; 69% as parent drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Andolina JR, Neudorf SM, and Corey SJ, &ldquo;How I Treat: Childhood CML,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 119(8):1821-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/1/29720/abstract-text/22210880/pubmed\" id=\"22210880\" target=\"_blank\">",
"        22210880",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baccarani M, Cortes J, Pane F, et al, &ldquo;Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(35):6041-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/1/29720/abstract-text/19884523/pubmed\" id=\"19884523\" target=\"_blank\">",
"        19884523",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cornelison M, Jabbour EJ, and Welch MA, &ldquo;Managing Side Effects of Tyrosine Kinase Inhibitor Therapy to Optimize Adherence in Patients With Chronic Myeloid Leukemia: The Role of the Midlevel Practitioner,&rdquo;",
"      <i>",
"       J Support Oncol",
"      </i>",
"      , 2012, 10(1):14-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/1/29720/abstract-text/22244674/pubmed\" id=\"22244674\" target=\"_blank\">",
"        22244674",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cortes JE, Hochhaus A, le Coutre PD, et al, &ldquo;Minimal Cross-Intolerance With Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated Phase Who are Intolerant to Imatinib,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 117(21):5600-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/1/29720/abstract-text/21467546/pubmed\" id=\"21467546\" target=\"_blank\">",
"        21467546",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hamnvik OP, Larsen PR, and Marqusee E, &ldquo;Thyroid Dysfunction From Antineoplastic Agents,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2011, 103(21):1572-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/1/29720/abstract-text/22010182/pubmed\" id=\"22010182\" target=\"_blank\">",
"        22010182",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jabbour E, Kantarjian HM, O'Brien S, et al, &ldquo;Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What is the Optimal Response?&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2011, 29(32):4260-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/1/29720/abstract-text/21990394/pubmed\" id=\"21990394\" target=\"_blank\">",
"        21990394",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kantarjian HM, Giles FJ, Bhalla KN, et al, &ldquo;Nilotinib is Effective in Patients With Chronic Myeloid Leukemia in Chronic Phase After Imatinib Resistance or Intolerance: 24-Month Follow-Up Results,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 117(4):1141-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/1/29720/abstract-text/21098399/pubmed\" id=\"21098399\" target=\"_blank\">",
"        21098399",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kantarjian HM, Giles F, Gattermann N, et al, &ldquo;Nilotinib (Formerly AMN107), a Highly Selective Bcr-Abl Tyrosine Kinase Inhibitor, is Effective in Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in Chronic Phase Following Imatinib Resistance and Intolerance,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2007, 110(10):3540-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/1/29720/abstract-text/17715389/pubmed\" id=\"17715389\" target=\"_blank\">",
"        17715389",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kantarjian H, Giles F, Wunderle L, et al, &ldquo;Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome-Positive ALL,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(24):2542-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/1/29720/abstract-text/16775235/pubmed\" id=\"16775235\" target=\"_blank\">",
"        16775235",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kantarjian HM, Hochhaus A, Saglio G, et al, &ldquo;Nilotinib Versus Imatinib for the Treatment of Patients With Newly Diagnosed Chronic Phase, Philadelphia Chromosome-Positive, Chronic Myeloid Leukaemia: 24-Month Minimum Follow-Up of the Phase 3 Randomised ENESTnd Trial,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2011, 12(9):841-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/1/29720/abstract-text/21856226/pubmed\" id=\"21856226\" target=\"_blank\">",
"        21856226",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kl&uuml;mpen HJ, Samer CF, Mathijssen RH, et al, &ldquo;Moving Towards Dose Individualization of Tyrosine Kinase Inhibitors,&rdquo;",
"      <i>",
"       Cancer Treat Rev",
"      </i>",
"      , 2011, 37(4):251-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/1/29720/abstract-text/20833478/pubmed\" id=\"20833478\" target=\"_blank\">",
"        20833478",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Montemurro M, Sch&ouml;ffski P, Reichardt P, et al, &ldquo;Nilotinib in the Treatment of Advanced Gastrointestinal Stromal Tumours Resistant to Both Imatinib and Sunitinib,&rdquo;",
"      <i>",
"       Eur J Cancer",
"      </i>",
"      , 2009, 45(13):2293-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/1/29720/abstract-text/19467857/pubmed\" id=\"19467857\" target=\"_blank\">",
"        19467857",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nicolini FE, Turkina A, Shen ZX, et al, &ldquo;Expanding Nilotinib Access in Clinical Trials (ENACT): An Open-Label, Multicenter Study of Oral Nilotinib in Adult Patients With Imatinib-Resistant or Imatinib-Intolerant Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in the Chronic Phase,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2012, 118(1):118-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/1/29720/abstract-text/21732337/pubmed\" id=\"21732337\" target=\"_blank\">",
"        21732337",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saglio G, Kim DW, Issaragrisil S, et al, &ldquo;Nilotinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2010, 362(24):2251-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/1/29720/abstract-text/20525993/pubmed\" id=\"20525993\" target=\"_blank\">",
"        20525993",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weisberg E, Manley P, Mestan J, et al, &ldquo;AMN107 (Nilotinib): A Novel and Selective Inhibitor of BCR-ABL,&rdquo;",
"      <i>",
"       Br J Cancer",
"      </i>",
"      , 2006, 94(12):1765-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/1/29720/abstract-text/16721371/pubmed\" id=\"16721371\" target=\"_blank\">",
"        16721371",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9448 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-93.125.6.160-7DBF348CA4-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_1_29720=[""].join("\n");
var outline_f29_1_29720=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709171\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5501066\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6860243\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5501062\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5501140\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5501141\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5501142\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5501143\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5501144\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5501178\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5501060\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7885624\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5501171\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5501067\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13892804\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5501055\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5501103\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5501084\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5501085\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5501117\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5501116\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5501120\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5501069\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5501070\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5501082\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5501083\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5501123\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16321790\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5501173\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038900\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5501169\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5501131\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9448\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9448|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/9/18582?source=related_link\">",
"      Nilotinib: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_1_29721="Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults";
var content_f29_1_29721=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/1/29721/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/1/29721/contributors\">",
"     James N George, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/1/29721/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/1/29721/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/1/29721/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/1/29721/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/1/29721/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND DISEASE DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) are both acute syndromes with abnormalities in multiple organ systems and evidencing microangiopathic hemolytic anemia and thrombocytopenia. Although some studies appear to distinguish between TTP and HUS, the presenting features are essentially the same in most adult patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a few patients, neurologic abnormalities are dominant and acute renal failure is minimal or not present; these patients are considered by some to represent idiopathic or \"classical\" TTP.",
"     </li>",
"     <li>",
"      When acute renal failure is dominant, the disorder is considered by some to represent HUS.",
"     </li>",
"     <li>",
"      Among patients with the diagnosis of TTP supported by the presence of severe ADAMTS13 deficiency (activity &lt;10 percent), severe neurologic abnormalities and renal failure are both uncommon (",
"      <a class=\"graphic graphic_table graphicRef57941 \" href=\"UTD.htm?24/37/25180\">",
"       table 1",
"      </a>",
"      ). These data document that many patients with classical TTP have no or minimal neurologic abnormalities and renal function abnormalities, and that the presence of the &ldquo;classic pentad&rdquo; of clinical features is now rare, and may only occur in patients with additional or alternative diagnoses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, some patients present with severe neurologic abnormalities, such as seizures and coma, together with acute renal failure; these patients can best be described by the comprehensive term TTP-HUS. Common clinical usage has been to describe adults with these syndromes as having TTP, and children as having \"typical\" HUS if preceded by diarrhea caused by E. coli O157:H7 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=see_link&amp;anchor=H2#H2\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Evolution of disease definitions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=see_link&amp;anchor=H7#H7\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, all patients are diagnosed primarily by the presence of thrombocytopenia and microangiopathic hemolytic anemia without another clinically apparent cause, and most have some neurologic and renal abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Furthermore, the pathologic changes in patients described as TTP or HUS are identical and the initial treatment of all adult patients is the same: plasma exchange [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/1,3,6\">",
"     1,3,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of TTP-HUS in adults will be discussed here. Causes and treatment of TTP-HUS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=see_link\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42490?source=see_link\">",
"     \"Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL AND LABORATORY MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of TTP-HUS should be suspected when a patient presents with the characteristic set of clinical and laboratory findings without another clinically apparent etiology (",
"    <a class=\"graphic graphic_table graphicRef63416 \" href=\"UTD.htm?20/57/21404\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/2,3,7,8\">",
"     2,3,7,8",
"    </a>",
"    ]. These typically include a subset of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Microangiopathic hemolytic anemia (",
"      <a class=\"graphic graphic_picture graphicRef70851 \" href=\"UTD.htm?37/50/38694\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Thrombocytopenia, often with purpura but not usually severe bleeding",
"     </li>",
"     <li>",
"      Renal function may be normal, but acute renal insufficiency may be present, associated with anuria and may require acute dialysis",
"     </li>",
"     <li>",
"      Neurologic abnormalities, usually fluctuating, are common, but patients may have no neurologic abnormalities",
"     </li>",
"     <li>",
"      Fever is rare; high fever with chills suggests sepsis rather than TTP-HUS",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the era before effective treatment with plasma exchange, when the vast majority of patients died and the full clinical course of the untreated disease was observed, it was common for all of the above five features (\"the pentad\") to be present [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/7\">",
"     7",
"    </a>",
"    ].",
"    <strong>",
"     It is now rare for all components of the pentad to be present in the same individual",
"    </strong>",
"    (",
"    <a class=\"graphic graphic_table graphicRef57941 \" href=\"UTD.htm?24/37/25180\">",
"     table 1",
"    </a>",
"    )",
"    <strong>",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With the availability of curative plasma exchange therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/6\">",
"     6",
"    </a>",
"    ], only thrombocytopenia and microangiopathic hemolytic anemia without another clinically apparent etiology (eg, disseminated intravascular coagulation, malignant hypertension, severe preeclampsia, sepsis, systemic malignancy) are required to suspect the diagnosis of TTP-HUS and to initiate plasma exchange [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/1,9\">",
"     1,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although patients with TTP may have similar risks for venous thromboembolism (VTE) as other hospitalized patients, VTE is not a recognized clinical manifestation of TTP. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link&amp;anchor=H21#H21\">",
"     \"Overview of the causes of venous thrombosis\", section on 'Acquired thrombophilia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Microangiopathic hemolytic anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microangiopathic hemolytic anemia (MAHA) is the hallmark of these disorders and, along with thrombocytopenia, is a major diagnostic criterion. &nbsp;MAHA is defined as nonimmune hemolysis (ie, negative direct antiglobulin test) with prominent red cell fragmentation (schistocytes) observed on the peripheral blood smear (",
"    <a class=\"graphic graphic_picture graphicRef70851 \" href=\"UTD.htm?37/50/38694\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Red cell fragmentation can be extreme, even to the extent of decreasing the red cell mean corpuscular volume (MCV) and artifactually increasing the reported platelet count when these smaller red cells are counted as platelets in some automated instruments. However, red cell fragmentation and anemia may be mild at the time of a patient&rsquo;s initial presentation and only become severe within the first several days after diagnosis.",
"   </p>",
"   <p>",
"    Patients have the typical findings of hemolysis, including elevation of the serum indirect bilirubin concentration and reduction in the serum haptoglobin concentration. The serum lactate dehydrogenase (LDH) level is typically extremely high, reflecting both hemolysis and tissue damage due to systemic ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/10\">",
"     10",
"    </a>",
"    ]. Thus, the serum LDH is a useful parameter for both diagnosis as well as following the response to treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Definition of schistocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A frequently asked question has been how many schistocytes need to be present on a peripheral blood smear to suggest the diagnosis of fragmentation hemolysis. The answer requires some estimate of the prevalence of schistocytes in normal subjects.",
"   </p>",
"   <p>",
"    This issue was addressed in a study of 40 normal individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/11\">",
"     11",
"    </a>",
"    ]. Schistocytes were found on the peripheral blood smear in 23 (58 percent). However, they always comprised less than 0.5 percent of the red cell population, with a mean of 0.05 percent. In patients with renal disease, preeclampsia, and normally functioning mechanical heart valves, schistocytes were seen in 80 to 100 percent of cases, but also comprised a low percentage of red cells (0.2 to 0.3 percent).",
"   </p>",
"   <p>",
"    In contrast, the mean schistocyte count in six patients with TTP-HUS was 8.4 percent (range 1 to 18 percent). In the appropriate clinical setting and in absence of other known causes of thrombotic microangiopathy, the authors concluded that a schistocyte count &gt;1.0 percent was strongly suggestive of a diagnosis of TTP-HUS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/11\">",
"     11",
"    </a>",
"    ]. Thus, observation of two or more schistocytes in a microscopic field at 100X magnification suggests the presence of microangiopathic hemolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=see_link&amp;anchor=H3#H3\">",
"     \"Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism\", section on 'Fragmentation hemolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rarely, TTP-HUS is diagnosed in the absence of red cell fragmentation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/12\">",
"     12",
"    </a>",
"    ]. This is most likely to occur early in the course of the disease, such as in patients who have recovered from a previous episode of TTP-HUS and are therefore being followed closely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombocytopenia is the other major diagnostic criterion for these disorders, and may be extreme. In one series of 135 patients, for example, the mean platelet count prior to treatment was",
"    <span class=\"nowrap\">",
"     25,300/microL",
"    </span>",
"    (range: 5 to",
"    <span class=\"nowrap\">",
"     120,000/microL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/13\">",
"     13",
"    </a>",
"    ]. In an analysis of 65 consecutive patients with severe ADAMTS13 deficiency (activity &lt;10 percent), the severity of thrombocytopenia was similar, with a median platelet count of",
"    <span class=\"nowrap\">",
"     16,000/microL",
"    </span>",
"    (range: 2000 to",
"    <span class=\"nowrap\">",
"     124,000/microL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/1\">",
"     1",
"    </a>",
"    ]. Thrombocytopenia may be less severe in patients who present with renal failure. This may be because syndromes classified as HUS, rather than TTP, may be distinct, and thrombocytopenia may be less severe in these syndromes. Alternatively, acute renal failure may be the dominant abnormality that initiates consideration of the diagnosis; in this setting, less severe thrombocytopenia is required for suspecting the diagnosis of TTP-HUS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal disease in TTP-HUS is due to a renal thrombotic microangiopathy, which is usually associated with a urinalysis that is often near normal with only mild proteinuria (usually between 1 to 2",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    and few cells or casts [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/2,14\">",
"     2,14",
"    </a>",
"    ]. However, glomerulonephritis or vasculitis may be suspected in some cases, since red cells and rarely red cell casts may be seen and hypocomplementemia occurs in approximately one-half of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. It is presumed that endothelial injury or bacterial or viral toxins are responsible for activation of the complement pathway. In view of these overlapping findings, the presence of thrombocytopenia may be the primary clue pointing toward TTP-HUS.",
"   </p>",
"   <p>",
"    Acute renal insufficiency may be associated with anuria, possibly requiring acute dialysis. This has been the characteristic presenting feature in 96 percent of our patients with TTP-HUS secondary to the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=see_link&amp;anchor=H21#H21\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Quinine'",
"    </a>",
"    .) Chronic kidney disease, as defined by a creatinine clearance &lt;60",
"    <span class=\"nowrap\">",
"     mL/minute,",
"    </span>",
"    is also common following quinine-induced TTP-HUS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/17\">",
"     17",
"    </a>",
"    ] but is rare in other TTP-HUS syndromes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Neurologic symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic symptoms and signs are present in many, but not all patients with TTP-HUS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. However, even in patients with typical TTP associated with severe acquired ADAMTS13 deficiency, approximately 30 to 60 percent of patients will have no neurologic abnormalities or only mild abnormalities such as confusion or headache [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/1,9,18\">",
"     1,9,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common neurologic symptoms in TTP-HUS are more subtle changes, such as confusion or severe headache. Focal, objective abnormalities (eg, transient aphasia, transient ischemic attack, stroke) are less frequent, but grand mal seizures and coma can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/19\">",
"     19",
"    </a>",
"    ]. Imaging studies using CT or MRI may show a pattern consistent with reversible posterior leukoencephalopathy syndrome (PRES) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/20-22\">",
"     20-22",
"    </a>",
"    ] but are more often normal. However, full neurologic recovery is possible even in comatose patients with extensive brain abnormalities on MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43273?source=see_link\">",
"     \"Reversible posterior leukoencephalopathy syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Abdominal symptoms of pain, nausea, vomiting, and diarrhea are the most common presenting symptoms of patients with severe acquired ADAMTS13 deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/1\">",
"     1",
"    </a>",
"    ]. These, along with the presence of severe neutrophilia, are also typical in children with typical HUS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/1,23\">",
"     1,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever is uncommon in more recent case series. However, the presence of chills and high, spiking fever should suggest the diagnosis of",
"    <span class=\"nowrap\">",
"     sepsis/infection",
"    </span>",
"    and DIC rather than TTP-HUS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'TTP-HUS versus DIC'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cardiac involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffuse platelet thrombi and associated hemorrhage and patches of necrosis in cardiac tissues (eg, coronary arteries, myocardium, conducting system) may lead to complications such as arrhythmia, sudden cardiac death, myocardial infarction, cardiogenic shock,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    heart failure in patients with TTP-HUS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/25-29\">",
"     25-29",
"    </a>",
"    ]. While the incidence of these cardiac changes is difficult to determine, continuing case reports and cohort studies suggest that such cardiac abnormalities may be important and often unrecognized causes of mortality and morbidity in TTP-HUS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/28-31\">",
"     28-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 220 adult patients with TTP-HUS, the incidence of acute heart failure was 9.5 percent, recognized on average eight days after the diagnosis of TTP-HUS was made [",
"      <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/29\">",
"       29",
"      </a>",
"      ]. In patients with an available baseline ejection fraction, the diagnosis of TTP-HUS was associated with an acute absolute reduction in ejection fraction of 31 percent. Mortality in TTP-HUS patients with heart failure was significantly greater than that in TTP-HUS patients without this complication (38 versus 17 percent).",
"     </li>",
"     <li>",
"      In a report covering 78 consecutive episodes of thrombotic microangiopathy seen at a single medical center, acute myocardial infarction (AMI) was diagnosed in 14 (18 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/28\">",
"       28",
"      </a>",
"      ]. A serum level of lactate dehydrogenase &gt;1000",
"      <span class=\"nowrap\">",
"       IU/L",
"      </span>",
"      in conjunction with a serum troponin I level &gt;0.20",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      at presentation had a sensitivity and specificity of 86 and 95 percent, respectively, to predict AMI in the later course of the thrombotic microangiopathy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     ADAMTS13 deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;TTP-HUS is a",
"    <strong>",
"     clinical",
"    </strong>",
"    diagnosis that must be made in a timely manner in order to initiate urgent intervention with plasma exchange. Assays for ADAMTS13, the von Willebrand factor cleaving protease, and its inhibitor are not always available, and, even if available, results may not be known for some time. Of importance, assay techniques for ADAMTS13 are not completely standardized and can yield different or inconsistent results, emphasizing that treatment decisions should not be based solely on activity assay results [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/5,32-34\">",
"     5,32-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 107 patients with idiopathic TTP-HUS (ie, not associated with a known cause), the finding of severe ADAMTS13 deficiency defined patients who have the characteristic, but variable, clinical features of TTP-HUS, and documented distinctions from patients who did not have severe ADAMTS13 deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/33\">",
"     33",
"    </a>",
"    ]. The presenting features of the 51 patients who had severe ADAMTS13 deficiency were highly variable, but there were distinctions from the 57 patients who did not have severe ADAMTS13 deficiency. Patients without severe ADAMTS13 deficiency were older, had less severe anemia and thrombocytopenia but more severe renal failure. Mortality was the same in both groups of patients, but patients without severe ADAMTS13 deficiency rarely relapsed, in contrast to the 40 percent relapse rate among patients with severe ADAMTS13 deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It can be concluded that the group of patients with severe ADAMTS13 deficiency does not include all patients who may be appropriately diagnosed with TTP-HUS and treated with plasma exchange [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/33,35-37\">",
"     33,35-37",
"    </a>",
"    ]. This observation supports the current practice of requiring ONLY thrombocytopenia and microangiopathic hemolytic anemia with no other apparent cause in order to make a clinical diagnosis of TTP-HUS.",
"   </p>",
"   <p>",
"    In patients who are found to have severe ADAMTS13 deficiency, it is common for the laboratory to test for the presence of an inhibitor of ADAMTS13 activity. An inhibitor is assumed to be an acquired autoantibody and is often said to distinguish acquired TTP-HUS from congenital ADAMTS13 deficiency. However, inhibitor activity may not always be identified in patients who have acquired ADAMTS13 deficiency documented by recovery of ADAMTS13 activity following successful treatment or documentation of an inhibitor at the time of a relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/33\">",
"     33",
"    </a>",
"    ]. The initial inability to demonstrate an ADAMTS13 inhibitor may be related to plasma infusion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    replacement or transfusion of blood products before a sample for ADAMTS13 activity is obtained.",
"   </p>",
"   <p>",
"    Thus, while testing for ADAMTS13 deficiency is important for understanding the pathogenesis of the congenital and acquired causes of this disorder and for anticipating the long term risk for relapse, it should not be used for confirming the diagnosis before treatment is initiated, since delays in initiating treatment may be fatal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42490?source=see_link&amp;anchor=H107006957#H107006957\">",
"     \"Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The uses of ADAMTS13 in understanding the pathogenesis of TTP-HUS and in following the results of treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=see_link&amp;anchor=H8#H8\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'ADAMTS13 deficiency'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42490?source=see_link&amp;anchor=H13594423#H13594423\">",
"     \"Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults\", section on 'Measurement of ADAMTS13 activity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13964768\">",
"    <span class=\"h3\">",
"     Congenital TTP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subjects with congenital TTP (Upshaw-Schulman syndrome) caused by absent or very low levels of ADAMTS13 activity may present during the neonatal period, during childhood, or not until adulthood. Congenital TTP may present as neonatal jaundice associated with hemolysis and thrombocytopenia that may be misdiagnosed as hemolytic disease of the newborn or alloimmune thrombocytopenia. It may present during childhood as recurrent episodes of thrombocytopenia, and be diagnosed as ITP if the microangiopathic hemolysis is not appreciated. For patients whose first presentation is during adulthood, common precipitating factors are infection (eg, influenza), pregnancy, surgery, and pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series of 29 patients with congenital TTP, ADAMTS13 levels &lt;2.74 percent of normal had a 92 percent sensitivity and 81 percent specificity for predicting an age at first TTP episode (requiring treatment with fresh frozen plasma) of less than 18 years of age. An ADAMTS13 level &lt;1.61 percent predicted for more than one episode of TTP per year with a sensitivity and specificity of 78 and 100 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a series of 43 Japanese patients with congenital TTP, the diagnosis was first made during adulthood in 42 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/38\">",
"       38",
"      </a>",
"      ]. Strong triggers for disease onset included pregnancy, influenza infection, and the administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      (dDAVP). Other influences in this group of patients included aging, interferon therapy, and excess alcohol ingestion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis of congenital TTP should be considered when the following scenarios are present [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The occurrence of thrombocytopenia and hemolytic anemia or severe neonatal jaundice requiring exchange transfusion in a newborn infant",
"     </li>",
"     <li>",
"      Recurrent episodes of acute thrombocytopenia in a child",
"     </li>",
"     <li>",
"      The diagnosis of TTP in a child, since TTP associated with acquired autoimmune ADAMTS13 deficiency is rare in children",
"     </li>",
"     <li>",
"      TTP occurring during an initial pregnancy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/56/38793?source=see_link&amp;anchor=H18#H18\">",
"       \"Thrombocytopenia in pregnancy\", section on 'TTP-HUS associated with pregnancy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis of congenital TTP is supported by demonstration of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Repeatedly low to absent levels of ADAMTS13 during clinical remission",
"     </li>",
"     <li>",
"      Absence of an inhibitor to ADAMTS13",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, some patients with acquired autoimmune ADAMTS13 deficiency may not have a demonstrable inhibitor when they are initially diagnosed, and may also have persistent severe ADAMTS13 deficiency, with or without a demonstrable inhibitor, during remission.",
"   </p>",
"   <p>",
"    The diagnosis of congenital TTP is confirmed by demonstration of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Homozygosity or compound heterozygosity for a mutation in the ADAMTS13 gene",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Genetic analysis can be obtained at no charge by enrolling patients in the Hereditary TTP (Upshaw-Schulman syndrome) Registry (",
"    <a class=\"external\" href=\"file://www.ttpregistry.net\">",
"     www.ttpregistry.net",
"    </a>",
"    ; NCT 01257269 at",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"     clinicaltrials.gov",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Associated conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most cases of TTP-HUS in adults are idiopathic, some patients will have a known associated condition or cause of TTP-HUS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=see_link\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    .) These include (",
"    <a class=\"graphic graphic_table graphicRef69868 \" href=\"UTD.htm?4/25/4508\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Bloody diarrhea",
"      </strong>",
"      &mdash; Bloody diarrhea caused by Shiga toxin-producing bacteria (eg, E coli O157:H7, 0104:H4, 0111) is the characteristic syndrome in young children and also occurs in adults, both sporadically as well as in epidemics [",
"      <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/41\">",
"       41",
"      </a>",
"      ]. However, bloody diarrhea may also occur in patients with severe ADAMTS13 deficiency due to mesenteric microthrombi, resulting in hemorrhagic mucosal ischemia and ulceration, pathologically similar to Shiga toxin-induced hemorrhagic enterocolitis [",
"      <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/9,41\">",
"       9,41",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35704?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children\", section on 'Clinical and laboratory manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Pregnancy",
"      </strong>",
"      &mdash; Development of symptoms during pregnancy, typically near term or early in the postpartum period. Pregnancy may be a trigger for the occurrence of acute episodes in patients with congenital or acquired severe ADAMTS13 deficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/42\">",
"       42",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/56/38793?source=see_link&amp;anchor=H18#H18\">",
"       \"Thrombocytopenia in pregnancy\", section on 'TTP-HUS associated with pregnancy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Drugs",
"      </strong>",
"      &mdash; Dose-dependent toxicity with certain drugs (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/16/38144?source=see_link\">",
"       mitomycin",
"      </a>",
"      C,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <strong>",
"       Other agents",
"      </strong>",
"      &mdash; A careful history is often required to establish the presence of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"       quinine",
"      </a>",
"      -induced disease. Initial or recurrent episodes can be triggered by quinine contained in beverages or nutrition health products (eg, tonic water, quinine water, or listed in other products as cinchona) (",
"      <a class=\"graphic graphic_table graphicRef60296 \" href=\"UTD.htm?21/20/21836\">",
"       table 4",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Systemic disorders to be considered",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of thrombocytopenia, microangiopathic hemolytic anemia, and renal failure can also be seen with a number of severe disorders, such as systemic vasculitis and malignant hypertension. Other causes of a microangiopathic picture are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=see_link&amp;anchor=H3#H3\">",
"     \"Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism\", section on 'Fragmentation hemolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Vasculitis and other connective tissue disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with vasculitis and other connective tissue diseases (eg, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA)) typically have other systemic symptoms (eg, arthralgias, rash) and the characteristic neurologic involvement may be peripheral (mononeuritis multiplex) or central (CNS lupus). Fever may be present, and the patient may be thrombocytopenic as the result of an autoimmune mechanism",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    platelet consumption secondary to a microangiopathic process (eg, accompanying malignant hypertension).",
"   </p>",
"   <p>",
"    Patients with active vasculitis, especially when complicated by severe hypertension and renal involvement, may be difficult to distinguish from idiopathic TTP, especially since some may have extremely low levels of ADAMTS13 along with the presence of IgG antibodies directed against ADAMTS13. Such cases may represent a true \"overlap\" syndrome between",
"    <span class=\"nowrap\">",
"     SLE/RA",
"    </span>",
"    and TTP [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/43-46\">",
"     43-46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14106?source=see_link&amp;anchor=H10#H10\">",
"     \"Hematologic manifestations of systemic lupus erythematosus in adults\", section on 'Microangiopathic hemolytic anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Catastrophic antiphospholipid syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The catastrophic antiphospholipid syndrome, characterized by widespread microvascular and macrovascular changes due to intravascular thrombosis, may be confused clinically with TTP-HUS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/47\">",
"     47",
"    </a>",
"    ]. The \"lupus anticoagulant\" present in this condition prolongs the aPTT, and occasionally the PT, which may be an important clue to the presence of this disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link&amp;anchor=H37#H37\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\", section on 'Catastrophic APS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Scleroderma renal crisis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with scleroderma renal crisis present with acute onset of renal failure, often in the absence of a prior history of renal disease, moderate to severe hypertension, and a microangiopathic blood picture with thrombocytopenia. Neurologic symptoms may also be present (eg, headache, blurred vision, seizures). Microscopic hematuria and granular casts can occur, as in any form of malignant hypertension.",
"   </p>",
"   <p>",
"    It may be difficult to separate this condition from TTP. The presence of stigmata of systemic sclerosis and specific autoantibodies such as anticentromere (ACA), anti-topoisomerase-I (Scl-70), and anti-RNA polymerase antibodies are supportive of the diagnosis of systemic sclerosis (scleroderma), while a low level (ie, &lt;10 percent) of ADAMTS13 favors the diagnosis of TTP [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43095?source=see_link\">",
"     \"Diagnosis and differential diagnosis of systemic sclerosis (scleroderma) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rapid control of the hypertension, rather than plasma exchange, is essential for the effective treatment of this disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35801?source=see_link&amp;anchor=H18#H18\">",
"     \"Scleroderma renal crisis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Malignant hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of malignant hypertension is usually made from the history of uncontrolled hypertension, a diastolic pressure that is typically above 130 mmHg, and hemorrhages and papilledema on retinal examination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=see_link\">",
"     \"Malignant hypertension and hypertensive encephalopathy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Microangiopathic changes can also be seen in patients with severe hypertension as part of vasculitis in systemic lupus erythematosus or scleroderma. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Vasculitis and other connective tissue disease'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H16\">",
"     'Scleroderma renal crisis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     TTP-HUS versus DIC",
"    </span>",
"    &nbsp;&mdash;&nbsp;The distinction between TTP-HUS and disseminated intravascular coagulation (DIC) may be difficult, and is based upon the history and laboratory studies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/49\">",
"     49",
"    </a>",
"    ]. DIC is associated with different disorders from TTP-HUS, such as sepsis, shock, or an obstetrical complication including severe preeclampsia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/56/8073?source=see_link\">",
"     \"Pathogenesis and etiology of disseminated intravascular coagulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These conditions are associated with intravascular activation of the coagulation cascade (usually mediated by procoagulants such as tissue factor and cancer procoagulant), leading to intravascular deposition of fibrin thrombi (rather than the platelet-rich thrombi characteristic of TTP-HUS), the consumption of all of the components of the coagulation cascade, and microangiopathic hemolytic anemia. As a result, patients with DIC typically have thrombocytopenia, low circulating levels of fibrinogen and factors V and VIII, and prolongation of the prothrombin and partial thromboplastin times (PT and aPTT, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In comparison, TTP-HUS represents platelet consumption due to endothelial injury or a primary increase in platelet activation without activation of the coagulation cascade [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/2,50\">",
"     2,50",
"    </a>",
"    ]. The net effect is thrombocytopenia, increased turnover of platelets but not fibrin, and usually normal levels of the coagulation components and little or no prolongation of the PT or aPTT (",
"    <a class=\"graphic graphic_table graphicRef63416 \" href=\"UTD.htm?20/57/21404\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    However, severe DIC caused by sepsis can mimic the multi-organ involvement of TTP-HUS, including the occurrence of severe ADAMTS13 deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/24,51\">",
"     24,51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=see_link&amp;anchor=H11#H11\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'ADAMTS13 activity in other conditions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some systemic infections, such as aspergillus and cytomegalovirus, can cause severe vascular and end-organ damage, leading to microangiopathic hemolytic anemia in addition to thrombocytopenia. These laboratory signs are often initially interpreted as representing TTP-HUS, but specific antimicrobial treatment, rather than plasmapheresis, is required [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Postpartum acute renal failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postpartum acute renal failure is a relatively common setting in which this differential must be made. Postpartum TTP-HUS is a relatively rare disorder, being much less common than severe preeclampsia or eclampsia with superimposed DIC. Making this distinction is important clinically, since preeclampsia tends to resolve spontaneously within several days after delivery, whereas TTP-HUS may lead to progressive renal failure and death. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33479?source=see_link\">",
"     \"Acute kidney injury (acute renal failure) in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Disseminated malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with previously untreated disseminated, often occult, mucin-producing adenocarcinomas may present with a clinical picture resembling TTP. A search for systemic malignancy, including a bone marrow biopsy, is appropriate when patients with a working diagnosis of TTP-HUS have atypical clinical features or fail to respond to plasma exchange. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=see_link&amp;anchor=H27#H27\">",
"     \"Hypercoagulable disorders associated with malignancy\", section on 'Disseminated malignancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of TTP-HUS is generally made on clinical grounds from the following characteristic clinical and laboratory findings (",
"    <a class=\"graphic graphic_table graphicRef63416 \" href=\"UTD.htm?20/57/21404\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Microangiopathic hemolytic anemia (",
"      <a class=\"graphic graphic_picture graphicRef70851 \" href=\"UTD.htm?37/50/38694\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Thrombocytopenia",
"     </li>",
"     <li>",
"      Acute renal insufficiency of varying degrees of severity",
"     </li>",
"     <li>",
"      Neurologic abnormalities, usually fluctuating",
"     </li>",
"     <li>",
"      Fever",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With the availability of curative plasma exchange therapy, only thrombocytopenia and microangiopathic hemolytic anemia without another clinically apparent etiology are required to suspect the diagnosis of TTP-HUS and to initiate plasma exchange. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Clinical and laboratory manifestations'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H10\">",
"     'ADAMTS13 deficiency'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42490?source=see_link&amp;anchor=H7729522#H7729522\">",
"     \"Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults\", section on 'Plasma exchange indications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Renal biopsy may be helpful in selected patients in whom the diagnosis is uncertain and thrombocytopenia is not limiting (",
"    <a class=\"graphic graphic_picture graphicRef63511 graphicRef54840 graphicRef69687 graphicRef78330 graphicRef75317 \" href=\"UTD.htm?43/7/44154\">",
"     picture 2A-E",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=see_link&amp;anchor=H6#H6\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'Pathology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     ADDITIONAL INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional information concerning thrombocytopenic conditions (ie, drug-induced, ITP, TTP-HUS, and thrombocytopenia in pregnancy) can be found on a website maintained and updated by Dr. James N. George at the University of Oklahoma Health Sciences Center:",
"    <a class=\"external\" href=\"file://www.ouhsc.edu/platelets\">",
"     www.ouhsc.edu/platelets",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29721/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Suspecting the diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) is made on clinical grounds from both characteristic clinical and laboratory findings (",
"    <a class=\"graphic graphic_table graphicRef63416 \" href=\"UTD.htm?20/57/21404\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Clinical and laboratory manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Clinical features",
"      <strong>",
"       required",
"      </strong>",
"      for the diagnosis of TTP-HUS:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Microangiopathic hemolytic anemia (",
"      <a class=\"graphic graphic_picture graphicRef70851 \" href=\"UTD.htm?37/50/38694\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Thrombocytopenia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Clinical features that",
"      <strong>",
"       may be present",
"      </strong>",
"      in some patients with TTP-HUS:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Acute renal insufficiency of varying degrees of severity",
"     </li>",
"     <li>",
"      Neurologic abnormalities, usually fluctuating",
"     </li>",
"     <li>",
"      Fever (but not high, spiking fever with chills, which suggest",
"      <span class=\"nowrap\">",
"       infection/sepsis/DIC)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Confirming the diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For the purposes of treatment, only the presence of microangiopathic hemolytic anemia and thrombocytopenia without other cause is sufficient to make an initial diagnosis of TTP-HUS and initiate treatment with plasma exchange. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Diagnostic criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Idiopathic TTP-HUS, a term used to describe patients without an associated condition such as pregnancy, systemic lupus erythematosus, or a possible drug etiology, is often associated with markedly reduced levels of ADAMTS13 (&lt;10 percent), usually with the presence of an inhibitor (autoantibody) of ADAMTS13 activity. However, results of these tests should not influence the initial treatment decision to initiate plasma exchange. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'ADAMTS13 deficiency'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of conditions may be confused with TTP-HUS. The distinction is important since response to plasma exchange is not expected for these conditions, which include the following (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Differential diagnosis'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Vasculitis and other connective tissue disorders",
"     </li>",
"     <li>",
"      Catastrophic antiphospholipid syndrome",
"     </li>",
"     <li>",
"      Scleroderma renal crisis",
"     </li>",
"     <li>",
"      Malignant hypertension",
"     </li>",
"     <li>",
"      Systemic infection with disseminated intravascular coagulation",
"     </li>",
"     <li>",
"      Disseminated malignancy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If malignant hypertension, infection, or malignancy is identified as the cause of the clinical features, plasma exchange should not be initiated or, if it has been initiated, it should be stopped.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/1\">",
"      George JN. How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood 2010; 116:4060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/2\">",
"      Remuzzi G. HUS and TTP: variable expression of a single entity. Kidney Int 1987; 32:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/3\">",
"      Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 2001; 60:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/4\">",
"      Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/5\">",
"      Tsai HM. Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. J Am Soc Nephrol 2003; 14:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/6\">",
"      Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991; 325:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/7\">",
"      Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: Report of 16 cases and review of the literature. Medicine (Baltimore) 1966; 45:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/8\">",
"      Siegler R, Berry PL, Hogg RL. Comparison of the epidemiologic and clinical features of endemic and sporadic forms of hemolytic-uremic syndrome (HUS) in 210 USA children. Report of the Southwest Pediatric Nephrology Study Group (abstract). Kidney Int 1986; 29:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/9\">",
"      George JN. Clinical practice. Thrombotic thrombocytopenic purpura. N Engl J Med 2006; 354:1927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/10\">",
"      Cohen JA, Brecher ME, Bandarenko N. Cellular source of serum lactate dehydrogenase elevation in patients with thrombotic thrombocytopenic purpura. J Clin Apher 1998; 13:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/11\">",
"      Burns ER, Lou Y, Pathak A. Morphologic diagnosis of thrombotic thrombocytopenic purpura. Am J Hematol 2004; 75:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/12\">",
"      Fava S, Galizia AC. Thrombotic thrombocytopenic purpura-like syndrome in the absence of schistocytes. Br J Haematol 1995; 89:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/13\">",
"      Rock G, Kelton JG, Shumak KH, et al. Laboratory abnormalities in thrombotic thrombocytopenic purpura. Canadian Apheresis Group. Br J Haematol 1998; 103:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/14\">",
"      Eknoyan G, Riggs SA. Renal involvement in patients with thrombotic thrombocytopenic purpura. Am J Nephrol 1986; 6:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/15\">",
"      Hebert LA, Cosio FG, Neff JC. Diagnostic significance of hypocomplementemia. Kidney Int 1991; 39:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/16\">",
"      Kojouri K, Vesely SK, George JN. Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: frequency, clinical features, and long-term outcomes. Ann Intern Med 2001; 135:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/17\">",
"      Vesely SK, George JN, Raskob GE. Long term clinical outcomes of thrombotic thrombocytopenic purpura-hemolytic-uremic syndrome (TTP-HUS) among different patient groups (abstract). Blood 1999; 94:15a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/18\">",
"      Sadler JE, Moake JL, Miyata T, George JN. Recent advances in thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program 2004; :407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/19\">",
"      Scully M, Yarranton H, Liesner R, et al. Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haematol 2008; 142:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/20\">",
"      Hawley JS, Ney JP, Swanberg MM. Thrombotic thrombocytopenic purpura-induced posterior leukoencephalopathy in a patient without significant renal or hypertensive complications. J Postgrad Med 2004; 50:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/21\">",
"      Bakshi R, Shaikh ZA, Bates VE, Kinkel PR. Thrombotic thrombocytopenic purpura: brain CT and MRI findings in 12 patients. Neurology 1999; 52:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/22\">",
"      Burrus TM, Wijdicks EF, Rabinstein AA. Brain lesions are most often reversible in acute thrombotic thrombocytopenic purpura. Neurology 2009; 73:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/23\">",
"      Vierzig A, Roth B, Querfeld U, Michalk D. A 12-year-old boy with fatal hemolytic-uremic-syndrome, excessive neutrophilia and elevated endogenous granulocyte-colony-stimulating-factor serum concentrations. Clin Nephrol 1998; 50:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/24\">",
"      Booth KK, Terrell DR, Vesely SK, George JN. Systemic infections mimicking thrombotic thrombocytopenic purpura. Am J Hematol 2011; 86:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/25\">",
"      Ridolfi RL, Hutchins GM, Bell WR. The heart and cardiac conduction system in thrombotic thrombocytopenic purpura. A clinicopathologic study of 17 autopsied patients. Ann Intern Med 1979; 91:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/26\">",
"      Podolsky SH, Zembowicz A, Schoen FJ, et al. Massive myocardial necrosis in thrombotic thrombocytopenic purpura: a case report and review of the literature. Arch Pathol Lab Med 1999; 123:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/27\">",
"      Wajima T, Johnson EH. Sudden cardiac death from thrombotic thrombocytopenic purpura. Clin Appl Thromb Hemost 2000; 6:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/28\">",
"      Patschan D, Witzke O, D&uuml;hrsen U, et al. Acute myocardial infarction in thrombotic microangiopathies--clinical characteristics, risk factors and outcome. Nephrol Dial Transplant 2006; 21:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/29\">",
"      Gami AS, Hayman SR, Grande JP, Garovic VD. Incidence and prognosis of acute heart failure in the thrombotic microangiopathies. Am J Med 2005; 118:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/30\">",
"      Hawkins BM, Abu-Fadel M, Vesely SK, George JN. Clinical cardiac involvement in thrombotic thrombocytopenic purpura: a systematic review. Transfusion 2008; 48:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/31\">",
"      Hughes C, McEwan JR, Longair I, et al. Cardiac involvement in acute thrombotic thrombocytopenic purpura: association with troponin T and IgG antibodies to ADAMTS 13. J Thromb Haemost 2009; 7:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/32\">",
"      Peyvandi F, Palla R, Lotta LA, et al. ADAMTS-13 assays in thrombotic thrombocytopenic purpura. J Thromb Haemost 2010; 8:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/33\">",
"      Kremer Hovinga JA, Vesely SK, Terrell DR, et al. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010; 115:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/34\">",
"      Froehlich-Zahnd R, George JN, Vesely SK, et al. Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura. Haematologica 2012; 97:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/35\">",
"      Raife T, Atkinson B, Montgomery R, et al. Severe deficiency of VWF-cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients. Transfusion 2004; 44:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/36\">",
"      Wolf G. Not known from ADAM(TS-13)--novel insights into the pathophysiology of thrombotic microangiopathies. Nephrol Dial Transplant 2004; 19:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/37\">",
"      Peyvandi F, Ferrari S, Lavoretano S, et al. von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura. Br J Haematol 2004; 127:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/38\">",
"      Fujimura Y, Matsumoto M, Isonishi A, et al. Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan. J Thromb Haemost 2011; 9 Suppl 1:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/39\">",
"      Lotta LA, Wu HM, Mackie IJ, et al. Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura. Blood 2012; 120:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/40\">",
"      George JN. Forecasting the future for patients with hereditary TTP. Blood 2012; 120:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/41\">",
"      Karpac CA, Li X, Terrell DR, et al. Sporadic bloody diarrhoea-associated thrombotic thrombocytopenic purpura-haemolytic uraemic syndrome: an adult and paediatric comparison. Br J Haematol 2008; 141:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/42\">",
"      Moatti-Cohen M, Garrec C, Wolf M, et al. Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood 2012; 119:5888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/43\">",
"      Shah AA, Higgins JP, Chakravarty EF. Thrombotic microangiopathic hemolytic anemia in a patient with SLE: diagnostic difficulties. Nat Clin Pract Rheumatol 2007; 3:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/44\">",
"      Musio F, Bohen EM, Yuan CM, Welch PG. Review of thrombotic thrombocytopenic purpura in the setting of systemic lupus erythematosus. Semin Arthritis Rheum 1998; 28:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/45\">",
"      Dold S, Singh R, Sarwar H, et al. Frequency of microangiopathic hemolytic anemia in patients with systemic lupus erythematosus exacerbation: Distinction from thrombotic thrombocytopenic purpura, prognosis, and outcome. Arthritis Rheum 2005; 53:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/46\">",
"      Matsuyama T, Kuwana M, Matsumoto M, et al. Heterogeneous pathogenic processes of thrombotic microangiopathies in patients with connective tissue diseases. Thromb Haemost 2009; 102:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/47\">",
"      Cerveny KC, Sawitzke AD. Relapsing catastrophic antiphospholipid antibody syndrome: a mimic for thrombotic thrombocytopenic purpura? Lupus 1999; 8:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/48\">",
"      Manadan AM, Harris C, Block JA. Thrombotic thrombocytopenic purpura in the setting of systemic sclerosis. Semin Arthritis Rheum 2005; 34:683.",
"     </a>",
"    </li>",
"    <li>",
"     Marder VJ, Martin SE, Francis CW, Colman RW. Consumptive thrombo-hemorrhagic disorders. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 2nd ed, Colman RW, Hirsh J, Marder VJ, Salzman EW (Eds), Lippincott, Philadelphia 1987. p.975.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/50\">",
"      Neame PB, Hirsh J, Browman G, et al. Thrombotic thrombocytopenic purpura: a syndrome of intravascular platelet consumption. Can Med Assoc J 1976; 114:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/51\">",
"      Ono T, Mimuro J, Madoiwa S, et al. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood 2006; 107:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/52\">",
"      Robboy SJ, Salisbury K, Ragsdale B, et al. Mechanism of Aspergillus-induced microangiopathic hemolytic anemia. Arch Intern Med 1971; 128:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29721/abstract/53\">",
"      Jeejeebhoy FM, Zaltzman JS. Thrombotic microangiopathy in association with cytomegalovirus infection in a renal transplant patient: a new treatment strategy. Transplantation 1998; 65:1645.",
"     </a>",
"    </li>",
"    <li>",
"     Search on \"TTP-HUS\". www.ouhsc.edu/platelets (Accessed on April 29, 2009).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1338 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-05EE575892-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_1_29721=[""].join("\n");
var outline_f29_1_29721=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND DISEASE DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL AND LABORATORY MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Microangiopathic hemolytic anemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Definition of schistocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Renal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Neurologic symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cardiac involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ADAMTS13 deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13964768\">",
"      - Congenital TTP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Associated conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Systemic disorders to be considered",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Vasculitis and other connective tissue disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Catastrophic antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Scleroderma renal crisis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Malignant hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TTP-HUS versus DIC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Postpartum acute renal failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Disseminated malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      DIAGNOSTIC CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      ADDITIONAL INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Suspecting the diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Confirming the diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/1338\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1338|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/50/38694\" title=\"picture 1\">",
"      Schistocytes on peripheral smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/51/22329\" title=\"picture 2A\">",
"      HUS Glomerular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/61/12246\" title=\"picture 2B\">",
"      HUS Vascular I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/49/26389\" title=\"picture 2C\">",
"      HUS Vascular II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/19/34099\" title=\"picture 2D\">",
"      HUS vascular III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/3/8255\" title=\"picture 2E\">",
"      HUS IF IV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1338|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/37/25180\" title=\"table 1\">",
"      Clinical features of decreased ADAMTS13 activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/57/21404\" title=\"table 2\">",
"      Lab findings TTP HUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/25/4508\" title=\"table 3\">",
"      Major causes of TTP-HUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/20/21836\" title=\"table 4\">",
"      Sources of quinine",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33479?source=related_link\">",
"      Acute kidney injury (acute renal failure) in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=related_link\">",
"      Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=related_link\">",
"      Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35704?source=related_link\">",
"      Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43095?source=related_link\">",
"      Diagnosis and differential diagnosis of systemic sclerosis (scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=related_link\">",
"      Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14106?source=related_link\">",
"      Hematologic manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35514?source=related_link\">",
"      Hypercoagulable disorders associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=related_link\">",
"      Malignant hypertension and hypertensive encephalopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/56/8073?source=related_link\">",
"      Pathogenesis and etiology of disseminated intravascular coagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43273?source=related_link\">",
"      Reversible posterior leukoencephalopathy syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35801?source=related_link\">",
"      Scleroderma renal crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/56/38793?source=related_link\">",
"      Thrombocytopenia in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42490?source=related_link\">",
"      Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_1_29722="Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction";
var content_f29_1_29722=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/1/29722/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/1/29722/contributors\">",
"     Jeffrey A Breall, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/1/29722/contributors\">",
"     Michael Simons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/1/29722/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/1/29722/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/1/29722/contributors\">",
"     Stephan Windecker, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/1/29722/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/1/29722/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/1/29722/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;At present, most patients with a non-ST elevation acute coronary syndrome (unstable angina [UA] and non-ST elevation myocardial infarction [NSTEMI]) in the United States, and many patients elsewhere, undergo coronary arteriography and revascularization during the index hospitalization. This topic will summarize the relevant evidence and make recommendations for the use of this early invasive approach. The pertinent clinical trials will be briefly mentioned here and are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29257?source=see_link\">",
"     \"Trials of conservative versus early invasive therapy in unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnostic evaluation of a non-ST elevation acute coronary syndrome (ACS) and the general management of these patients are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15034?source=see_link\">",
"     \"Initial evaluation and management of suspected acute coronary syndrome in the emergency department\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=see_link\">",
"     \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two issues that need to be clarified in patients with a non-ST elevation ACS: the definitions of UA and NSTEMI; and the definitions of early invasive and early conservative strategies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     UA and NSTEMI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unstable angina and NSTEMI are part of the continuum of acute coronary syndrome (ACS). In recognition of the diagnostic and prognostic importance of elevations in serum troponins and that some patients have atypical symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a nondiagnostic ECG, a joint American College of",
"    <span class=\"nowrap\">",
"     Cardiology/European",
"    </span>",
"    Society of Cardiology committee defined an acute, evolving, or recent MI as being present when there is a typical rise and gradual fall (troponin) or more rapid rise and fall (CK-MB) of biochemical markers of myocardial necrosis with at least one of the following [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ischemic symptoms",
"     </li>",
"     <li>",
"      Development of pathologic Q waves on the ECG",
"     </li>",
"     <li>",
"      ECG changes indicative of ischemia (ST segment elevation or depression)",
"     </li>",
"     <li>",
"      Coronary artery revascularization",
"     </li>",
"     <li>",
"      Pathologic findings of a healed or healing myocardial infarction",
"     </li>",
"     <li>",
"      Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    According to this definition and the American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACCF/AHA)",
"    </span>",
"    guidelines, UA and NSTEMI differ primarily in whether the ischemia is severe enough to cause sufficient myocardial damage to release detectable quantities of a marker of myocardial injury [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=see_link&amp;anchor=H2#H2\">",
"     \"Criteria for the diagnosis of acute myocardial infarction\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    UA is considered to be present in patients with ischemic symptoms suggestive of an ACS and no elevation in troponins or CK-MB, with or without ECG changes indicative of ischemia (eg, ST segment depression or transient elevation or new T wave inversion). Since an elevation in troponins",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CK-MB may not be detectable for hours after presentation, UA and NSTEMI are frequently indistinguishable at initial evaluation. ST segment",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    T wave changes are often persistent in NSTEMI while, if they occur in UA, they are usually transient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Early invasive and early conservative strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a consequence of the uncertainties in predicting the prognosis in patients without one of the indications for immediate coronary arteriography and revascularization described below, two major strategies were adopted: conservative and early invasive. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Indications for immediate angiography'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The early invasive strategy of coronary angiography followed by revascularization, if appropriate, is aimed at improving long-term prognosis. It involves prompt catheterization of all patients with UA or NSTEMI after the initiation of medical therapy, usually within 4 to 24 hours of admission. Most of the clinical trials have demonstrated a reduction in the incidence of death or nonfatal MI with an early invasive strategy, especially in high-risk patients.",
"   </p>",
"   <p>",
"    The American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/AHA",
"    </span>",
"    <span class=\"nowrap\">",
"     UA/STEMI",
"    </span>",
"    guidelines and their focused updates make a distinction between an early and a delayed invasive approach, with the latter being defined as diagnostic angiography after 24 hours and being acceptable in stable low to intermediate risk patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The conservative strategy begins with rapidly intensifying medical therapy. Patients who become asymptomatic on this regimen are given several days to \"cool off,\" during which time intravenous medications are discontinued. If the patient remains symptom-free, stress testing is performed, most often with some form of myocardial imaging (nuclear or echocardiography). Persistence of symptoms, symptom recurrence, or a positive stress test should lead to prompt cardiac catheterization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=see_link\">",
"     \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     GENERAL ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients presenting with an NSTEMI have a long-term outcome that is similar to that with an STEMI and worse than that in patients with UA [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/5\">",
"     5",
"    </a>",
"    ]. The similarity in prognosis in patients with non-ST elevation and ST elevation MI is in part related to more than a 50 percent prevalence of multivessel disease in patients with NSTEMI [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/6\">",
"     6",
"    </a>",
"    ]. Patients with a non-ST elevation ACS also have a higher incidence of recurrent ischemia than those with an STEMI (35 versus 23 percent at one year in GUSTO-IIb) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/5\">",
"     5",
"    </a>",
"    ]. Thus, a significant amount of myocardium often remains at risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44361?source=see_link&amp;anchor=H20#H20\">",
"     \"Epidemiology of coronary heart disease\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The short- and long-term prognosis of patients with an NSTEMI is also related to the location of the infarct and the extent of myocardial damage. A report from the SPRINT registry found that patients with an anterior NSTEMI had, when compared to those with an",
"    <span class=\"nowrap\">",
"     inferior/lateral",
"    </span>",
"    wall NSTEMI, significant increase in the rate of in-hospital complications (heart failure and cardiogenic shock), in-hospital mortality (15 versus 10 percent), and recurrent infarction or cardiac death at one year (14.2 versus 4.8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Early risk assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individual patients with UA and NSTEMI are at widely varying risks of subsequent complications such as death, recurrent MI, or recurrent angina requiring revascularization. For this reason, early risk stratification is essential to identify patients who may benefit from an early invasive approach.",
"   </p>",
"   <p>",
"    Retrospective review of patient characteristics in the trials of conservative versus early invasive approaches, such as TIMI IIB and ESSENCE, as well as in the observational GRACE registry, has identified individual predictors of risk as well as risk models in these patients. The TIMI risk score is the most widely used of these models. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2746?source=see_link\">",
"     \"Risk stratification after unstable angina or non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a substudy of 4491 moderate and high risk ACS patients who were treated medically after angiography in the ACUITY trial, the most powerful predictors of ischemic outcomes at one year were angiographic rather than clinical [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/2/5162?source=see_link&amp;anchor=H33#H33\">",
"     \"Anticoagulant therapy in non-ST elevation acute coronary syndromes\", section on 'Bivalirudin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     TIMI risk score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TIMI risk score was developed in an attempt to risk stratify patients with UA or NSTEMI. It is a validated risk prediction model, based upon data from the TIMI 11B and ESSENCE trials [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/9\">",
"     9",
"    </a>",
"    ]. Seven variables at presentation were independently predictive of outcome. A value of one was assigned when a factor was present and 0 when it was absent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2746?source=see_link&amp;anchor=H7#H7\">",
"     \"Risk stratification after unstable angina or non-ST elevation myocardial infarction\", section on 'TIMI risk score'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &ge;65 years",
"     </li>",
"     <li>",
"      Presence of at least three risk factors for CHD",
"     </li>",
"     <li>",
"      Prior coronary stenosis of &ge;50 percent",
"     </li>",
"     <li>",
"      Presence of ST segment deviation on admission ECG",
"     </li>",
"     <li>",
"      At least two anginal episodes in prior 24 hours",
"     </li>",
"     <li>",
"      Elevated serum cardiac biomarkers",
"     </li>",
"     <li>",
"      Use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      in prior seven days",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A higher TIMI risk score correlated significantly with increased numbers of events (all-cause mortality, new or recurrent MI, or severe recurrent ischemia requiring revascularization) at 14 days (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?5/34/5665?source=see_link\">",
"     calculator 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Score of",
"      <span class=\"nowrap\">",
"       0/1",
"      </span>",
"      - 4.7 percent",
"     </li>",
"     <li>",
"      Score of 2 - 8.3 percent",
"     </li>",
"     <li>",
"      Score of 3 - 13.2 percent",
"     </li>",
"     <li>",
"      Score of 4 - 19.9 percent",
"     </li>",
"     <li>",
"      Score of 5 - 26.2 percent",
"     </li>",
"     <li>",
"      Score of",
"      <span class=\"nowrap\">",
"       6/7",
"      </span>",
"      - 40.9 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A potential limitation of the TIMI risk score in identifying patients at higher risk is that some patients who are troponin negative at baseline have an elevated value at 12 hours. A risk score has been devised and validated for identifying patients who are more likely to develop elevated troponins [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/11\">",
"     11",
"    </a>",
"    ]. The most important risk factors were any ST segment deviation, presentation less than eight hours from symptom onset, and no history of PCI. However, the score remained predictive in patients without ST segment deviation. The clinical utility of these observations is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Indications for immediate angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;An early invasive strategy is aimed at revascularization of a stenosed artery, which can prevent or minimize MI and improve long-term prognosis. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Early invasive and early conservative strategies'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    This should be distinguished from immediate attempts to attain reperfusion of an occluded artery in patients with an STEMI using fibrinolysis or primary PCI with the goal of limiting infarct size.",
"   </p>",
"   <p>",
"    While fibrinolysis is beneficial in patients with an STEMI, prospective trials have demonstrated that fibrinolytic therapy is not beneficial in UA or NSTEMI and may be harmful [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/1,12,13\">",
"     1,12,13",
"    </a>",
"    ]. Angioscopic studies have shown that the nonoccluding thrombi that are present are primarily grayish-white (ie, platelet-rich) in",
"    <span class=\"nowrap\">",
"     UA/NSTEMI,",
"    </span>",
"    and therefore less likely to respond to fibrinolytic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/14\">",
"     14",
"    </a>",
"    ], in contrast to almost always being reddish (ie, fibrin-rich) in patients with STEMI [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22421?source=see_link\">",
"     \"Fibrinolytic (thrombolytic) agents in unstable angina and acute non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Immediate intervention is not as necessary in non-ST elevation ACS, compared to STEMI, because of the 60 to 85 percent rate of at least partial patency of the effected artery [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/6,16-18\">",
"     6,16-18",
"    </a>",
"    ]. As a result, ongoing ischemia is more likely to be due to embolization and the resultant impairment of microvascular perfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a subset of patients with UA or NSTEMI are deemed to be at such high risk of death or a complicated MI that early coronary arteriography is recommended with an intention to proceed to immediate revascularization if possible [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemodynamic instability with or without cardiogenic shock. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Cardiogenic shock'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=see_link\">",
"       \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Severe left ventricular dysfunction or overt heart failure. Among patients with uncomplicated NSTEMI, those with significant left ventricular dysfunction (left ventricular ejection fraction [LVEF] &lt;40 percent) have more than a 50 percent probability of having multivessel coronary disease [",
"      <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/6\">",
"       6",
"      </a>",
"      ]. Such patients are likely to gain a long-term survival advantage from appropriate coronary revascularization.",
"     </li>",
"     <li>",
"      Recurrent or persistent rest angina despite intensive medical therapy.",
"     </li>",
"     <li>",
"      Mechanical complications (eg, acute mitral regurgitation, ventricular septal defect). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39225?source=see_link\">",
"       \"Mechanical complications of acute myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sustained ventricular tachycardia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=see_link\">",
"       \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The only reasons to exclude angiography in patients with any of the above risks would be if they would not consider revascularization or if they have underlying conditions that preclude PCI or coronary artery bypass grafting (CABG).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     BENEFIT AND TIMING OF EARLY INTERVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned in the preceding section, most patients with NTEMI ACS do not benefit from immediate angiography. However, two questions regarding the indications for and timing of angiography have been studied in these patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Is early intervention better than conservative care?",
"     </li>",
"     <li>",
"      Among those patients for whom early intervention is chosen, what is the optimal timing?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Trials showing benefit from early intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of randomized clinical trials have compared an early invasive to a conservative strategy in patients with a non-ST elevation ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/12,19-24\">",
"     12,19-24",
"    </a>",
"    ]. These trials are discussed in detail elsewhere, but a brief summary of the major findings and conclusions will be presented here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29257?source=see_link\">",
"     \"Trials of conservative versus early invasive therapy in unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the large FRISC II and TACTICS-TIMI 18 trials, the following general observations were made among patients in the early invasive arm [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/19,22,23\">",
"     19,22,23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coronary angiography revealed either normal vessels or no vessel with &ge;50 percent stenosis in 13 to 14 percent.",
"     </li>",
"     <li>",
"      Early revascularization was performed in 61 to 71 percent of patients.",
"     </li>",
"     <li>",
"      Among patients undergoing early revascularization, coronary artery bypass graft was performed in 33 to 42 percent of patients, most often for three vessel or left main disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     FRISC II trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the FRISC II trial, 2457 patients with unstable coronary disease were randomly assigned after 48 hours to an invasive or noninvasive approach [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/19\">",
"     19",
"    </a>",
"    ]. The following outcomes were observed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At six months the rate of death or MI was significantly lower in the invasive group (9.4 versus 12.1 percent in the noninvasive group); the difference was primarily due to a lower rate of MI (7.8 versus 10.1 percent). The invasive approach was also associated with a 50 percent reduction in angina and the need for readmission.",
"     </li>",
"     <li>",
"      The reduction in the rate of the combined end point of death or MI was sustained at one and five years [",
"      <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/20,25\">",
"       20,25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     TACTICS-TIMI 18 trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;TACTICS-TIMI 18 trial randomly assigned 2220 patients presenting with UA or an NSTEMI to an invasive strategy (catheterization within 4 to 48 hours and revascularization with angioplasty or CABG if feasible) or conservative medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/22\">",
"     22",
"    </a>",
"    ]. The following important observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At six months, the primary end point (death, MI, rehospitalization for an ACS) was significantly lower with an invasive strategy (15.9 versus 19.4 percent for conservative approach, odds ratio 0.78). This benefit was due to reductions in MI or rehospitalization for an ACS.",
"     </li>",
"     <li>",
"      The reduction in the primary end point with the invasive approach was seen only in those patients who had an elevation of serum troponin I concentration (&ge;0.1",
"      <span class=\"nowrap\">",
"       ng/mL)",
"      </span>",
"      upon presentation to the hospital [",
"      <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As stated above, the rate of death or MI was significantly lower in the invasive group in both the FRISC II and TACTICS-TIMI 18 trials. The benefit was primarily due to a lower rate of MI. There was no significant mortality benefit at six months in either trial, but in FRISC II there was a significant benefit at one year (2.2 versus 3.9 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     RITA 3 trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;RITA 3 compared early angiography and revascularization with conservative therapy in 1810 patients with a non-ST elevation ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/23\">",
"     23",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At four months, an early invasive strategy was associated with a lower rate of the co-primary end point of death, nonfatal MI, or refractory angina (9.6 versus 14.5 percent, odds ratio 0.66, 95% CI 0.51-0.85); this benefit was entirely due to a reduction in refractory angina (defined as an episode of angina with new ischemic ECG changes) and persisted at one year.",
"     </li>",
"     <li>",
"      At one year, there was no difference between the two groups in the co-primary end point of death or nonfatal MI (7.6 versus 8.3 percent, risk ratio 0.91, 95% CI 0.67-1.25).",
"     </li>",
"     <li>",
"      In contrast to the equivocal benefit at one year, prespecified follow-up at a median of five years revealed that the interventional group had significant reductions in death or nonfatal MI (16.6 versus 20.0 percent, odds ratio 0.78, 95% CI 0.61-0.99) and in cardiovascular death or nonfatal MI (12 versus 15 percent, odds ratio 0.74, 95% CI 0.56-0.97) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/27\">",
"       27",
"      </a>",
"      ]. The benefits were primarily seen in patients at highest risk (29.2 versus 48.5 percent, odds ratio 0.44, 95% CI 0.25-0.76), which is consistent with the TIMI risk score data.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The benefits of an early invasive strategy were similar and of the same magnitude at five year follow-up in both the RITA 3 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/27\">",
"     27",
"    </a>",
"    ] and FRISC II trials [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Meta-analyses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two meta-analyses demonstrated the benefits of an early invasive in non-ST elevation ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. The first meta-analysis of seven major trials with 9212 patients includes some older, non-contemporary trials such as VANQWISH and TIMI IIIB and did not include the later ICTUS trial cited below [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/28\">",
"     28",
"    </a>",
"    ]. It concluded that an early invasive strategy was preferred based upon findings of a significant reduction in mortality and nonfatal MI from hospital discharge to the end of follow-up, and with significant reductions in Canadian Cardiovascular Society class III-IV angina (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ) and in rehospitalization.",
"   </p>",
"   <p>",
"    In contrast to these overall long-term benefits, there was no significant reduction in death or nonfatal MI among patients without any elevation in serum troponins or other cardiac biomarker. This finding is consistent with the above suggestion of lack of significant benefit in patients at low risk (TIMI risk score 0 to 2) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The second meta-analysis of seven trials with 8375 patients also concluded that an early invasive approach was preferable to a conservative strategy, despite including the discordant results from the ICTUS trial described below [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/29\">",
"     29",
"    </a>",
"    ]. The following significant benefits were noted with an early invasive strategy at a mean follow-up of two years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A lower rate of all-cause mortality (4.9 versus 6.5 percent with conventional therapy, RR = 0.75, 95% CI 0.63-0.90).",
"     </li>",
"     <li>",
"      A lower rate of nonfatal myocardial infarction (7.6 versus 9.1 percent, RR = 0.83, 95% CI 0.72-0.96).",
"     </li>",
"     <li>",
"      A lower rate of rehospitalization for unstable angina at 13 months of follow-up (RR = 0.69, 95% CI 0.65-0.74).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Trials showing no benefit from early intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the above data, at least three randomized trials found no benefit from early intervention: the TIMI IIIB trial, which was performed in the early 1990s [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/13\">",
"     13",
"    </a>",
"    ], the VANQWISH trial, which had serious limitations such as lack of intervention in 44 percent of patients in the early invasive strategy group [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/30\">",
"     30",
"    </a>",
"    ], and the ICTUS trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     ICTUS trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ICTUS trial found no benefit from an early invasive compared to a selective invasive strategy in 1200 patients with a non-ST elevation ACS who had chest pain, an elevated serum cardiac troponin T, and either ECG evidence of ischemia or a documented history of coronary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. On subgroup analysis, the presence of other high-risk features (eg, older age, ST segment depression, or a more marked elevation in serum cardiac troponin T) did not predict a better outcome with an early invasive strategy in contrast to the findings in the other trials as noted above. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29257?source=see_link&amp;anchor=H14#H14\">",
"     \"Trials of conservative versus early invasive therapy in unstable angina and non-ST elevation myocardial infarction\", section on 'ICTUS trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It cannot be determined with complete confidence why the results in this trial are different from those in FRISC II, TACTICS-TIMI 18, RITA 3, and the two meta-analyses discussed above. A seemingly important factor is the high rate of late revascularization during hospitalization in the selective invasive group in ICTUS. The rate of revascularization at two days (almost all PCI) was, as expected, much higher in the early invasive group (56 versus 4 percent). The difference was smaller for revascularization during the initial hospitalization (76 versus 40 percent). The median time to PCI was 23 hours in the early invasive group compared to 283 hours (11.8 days) in the selective invasive group, which is much longer than the typical hospitalization for non-ST elevation acute coronary syndromes in the United States (less than 72 hours in uncomplicated cases).",
"   </p>",
"   <p>",
"    Other factors that might explain the differing findings between ICTUS and the other trials include differences in study design, differing definitions of periprocedural MI, and the intensity of lipid lowering therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Timing of early intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;We typically perform cardiac catheterization within 4 to 24 hours of admission. Factors that may impact timing include catheterization laboratory and staff availability, patient co-morbidities, and the cost of longer hospitalization.",
"   </p>",
"   <p>",
"    The optimal timing of catheterization and possible revascularization on those patients in whom early intervention (as opposed to conservative therapy) has been chosen has been evaluated in at least three randomized trials and one observational study. The data from these studies of PCI are conflicting as to the optimal timing.",
"   </p>",
"   <p>",
"    The TIMACS trial randomly assigned (but not in a 1:1 manner) 3031 patients with a non-ST elevation ACS to either early (coronary angiography &le;24 hours after randomization; median time 14 hours) or delayed intervention (coronary angiography &ge;36 hours after randomization; median time 50 hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/33\">",
"     33",
"    </a>",
"    ]. At six months there was no significant difference in the primary composite outcome of death, myocardial infarction, or stroke (9.6 versus 11.3 percent, early versus delayed). Post hoc analysis suggested benefit for intervention in the third of patients at the highest risk.",
"   </p>",
"   <p>",
"    In the smaller ISAR-COOL trial, 410 intermediate-to-high risk patients with a non-ST elevation ACS plus either ST segment depression or an elevation in serum troponin were randomly assigned to a very early versus very delayed invasive strategy (median time to catheterization 2.4 versus 86 hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/34\">",
"     34",
"    </a>",
"    ]. The early invasive strategy, when compared with the delayed invasive strategy, was associated with a significant reduction in death or large MI at 30 days (5.9 versus 11.6 percent). The benefit in ISAR-COOL may be attributable to the 86 hour delay for angiography in the delayed group. However, this long wait period is not representative of current practice in the United States.",
"   </p>",
"   <p>",
"    Two trials, OPTIMA and ABOARD, have compared outcomes in patients randomly assigned to either immediate (comparable to primary PCI for STEMI) or delayed catheterization. The small OPTIMA trial (n=142), which was stopped prematurely due to slow enrollment, found a significantly lower rate of the primary composite end point (death, nonfatal MI, or unplanned revascularization at 30 days) in patients randomly assigned to deferred (24 to 48 hours) as opposed to immediate PCI (39 versus 60 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ABOARD trial randomly assigned 352 high-risk (TIMI risk score &ge;3) (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?5/34/5665?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) patients with NSTEMI ACS to receive angiography and possible revascularization either immediately or during the next working day (between 8 and 60 hours after enrollment) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/36\">",
"     36",
"    </a>",
"    ]. The median time from randomization to sheath insertion was 70 minutes in the immediate intervention group and 21 hours in the delay intervention group. There was no significant difference in either the primary outcome of peak hospital troponin I value or the secondary combined outcome of death, MI, or urgent revascularization at one month follow up (13.7 versus 10.2 percent in the immediate and delayed groups, respectively).",
"   </p>",
"   <p>",
"    Based on the above studies, early intervention can be performed any time up to 48 hours in stable patients with non-ST elevation ACS. However, based at least in part on the findings in TIMACS, we believe that patients at very high risk, such as those with a TIMI risk score of five or greater (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?5/34/5665?source=see_link\">",
"     calculator 1",
"    </a>",
"    ), derive benefit from earlier intervention (probably before 24 hours) or as clinically indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Patients who derive benefit",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon data from the above trials, groups of patients with the following individual characteristics have been identified which derive benefit of an early invasive approach. Most of these features are included in the TIMI risk score (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?5/34/5665?source=see_link\">",
"     calculator 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elevated serum troponins in FRISC II and TACTICS-TIMI 18 [",
"      <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/26,37,38\">",
"       26,37,38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      ST depression on the ECG in FRISC II, TACTICS-TIMI 18, and TIMI IIIB [",
"      <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/22,37,39-41\">",
"       22,37,39-41",
"      </a>",
"      ] and, in FRISC II, the degree of and the number of leads with ST depression [",
"      <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Age greater than 65 in TIMI IIIB and TACTICS-TIMI 18, although the risk of a bleeding complication is increased [",
"      <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/12,42\">",
"       12,42",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29257?source=see_link&amp;anchor=H16#H16\">",
"       \"Trials of conservative versus early invasive therapy in unstable angina and non-ST elevation myocardial infarction\", section on 'Effect in the elderly'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When applied to TACTICS-TIMI 18, the TIMI risk score identified patients who might benefit from an early invasive strategy (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?5/34/5665?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/22\">",
"     22",
"    </a>",
"    ]. In terms of the primary end point (death, MI, rehospitalization for an ACS at six months), the following were observed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients at low risk (score 0 to 2), there was no difference in outcome between the invasive and conservative approaches (12.8 versus 11.8 percent).",
"     </li>",
"     <li>",
"      There was a significant reduction in the primary end point with the invasive approach in patients at intermediate risk (score 3 to 4, 16.1 versus 20.3 percent) and particularly in those at high risk (score 5 to 7, 19.5 versus 30.6 percent). Similarly, in the five-year follow-up from the RITA 3 trial, the benefit was primarily seen in patients at highest risk at presentation [",
"      <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of biomarker elevation and ST segment deviation are two of the TIMI risk score variables. However, a later analysis from TACTICS-TIMI 18 showed that the degree of troponin elevation and magnitude of ST segment deviation were independent predictors of an adverse outcome and of benefit from an early invasive strategy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although small elevations in cardiac enzymes in an ACS are thought to reflect small, localized areas of infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/44\">",
"     44",
"    </a>",
"    ], the adverse prognosis associated with this finding may also be related to worse underlying disease. In FRISC II and TACTICS-TIMI 18, any elevation in serum troponin T increased the likelihood of severe three vessel disease, an unstable plaque with thrombus and downstream microembolization, and impairment of coronary flow; these factors are all associated with an increased risk for reinfarction and death [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A variable definition of ST segment depression was used in the different trials. Some found an adverse effect of ST depression of &ge;0.1 mV (1 mm) in &ge;1 or &ge;2 leads [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/41\">",
"     41",
"    </a>",
"    ], while analyses of other trials documented an adverse effect from ST depression of &ge;0.05 mV (0.5 mm) in &ge;1 lead [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/22,37,46\">",
"     22,37,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to new ST segment depression and elevated serum troponins or refractory angina, the 2011",
"    <span class=\"nowrap\">",
"     ACCF/AHA",
"    </span>",
"    focused update of prior guidelines for the management of patients with unstable",
"    <span class=\"nowrap\">",
"     angina/non-ST",
"    </span>",
"    elevation MI made the following additional indications for an early invasive strategy in patients without contraindications or serous comorbidities [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/47\">",
"     47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recurrent ischemia at rest or with low level activity after medical therapy",
"     </li>",
"     <li>",
"      Sustained ventricular tachycardia or hemodynamic instability",
"     </li>",
"     <li>",
"      High risk findings during noninvasive testing",
"     </li>",
"     <li>",
"      Evidence of heart failure or new or worsening mitral regurgitation",
"     </li>",
"     <li>",
"      Prior PCI within six months or prior CABG",
"     </li>",
"     <li>",
"      High risk TIMI or GRACE score",
"     </li>",
"     <li>",
"      Left ventricular ejection fraction &lt;40 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Patients with CKD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic kidney disease (CKD) are at risk for worse outcomes after myocardial infarction, but also are more likely to suffer complications of cardiac catheterization, such as acute kidney injury or cholesterol embolism [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2746?source=see_link&amp;anchor=H6#H6\">",
"     \"Risk stratification after unstable angina or non-ST elevation myocardial infarction\", section on 'Early risk stratification'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/42/42665?source=see_link&amp;anchor=H29#H29\">",
"     \"Complications of diagnostic cardiac catheterization\", section on 'Acute renal failure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The issue of whether the benefits of an early invasive strategy found in the general population (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Patients who derive benefit'",
"    </a>",
"    above) apply to patients with CKD was evaluated in a 2009 systematic review of five trials that enrolled 1453 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/48\">",
"     48",
"    </a>",
"    ]. All patients had a glomerular filtration rate &lt;60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    . An early invasive strategy was associated with a nonsignificant reduction in all-cause mortality (RR 0.76, 95% CI 0.49-1.17) and nonfatal myocardial infarction (RR 0.78, 95% CI 0.52-1.16) at one year.",
"   </p>",
"   <p>",
"    This issue was addressed further in the SWEDEHEART registry of over 23,000 patients with NSTEMI who received either an invasive or a medical strategy and then were stratified into groups based on baseline estimated glomerular filtration rate (eGFR) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/49\">",
"     49",
"    </a>",
"    ]. The adjusted one-year mortality increased as the eGFR fell from normal to dialysis dependent with either therapy, but the relative difference between the two groups narrowed with a decline in eGFR. There was no significant difference in the hazard rate for mortality between the two groups when the eGFR was less than 30 to 59",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    .",
"   </p>",
"   <p>",
"    We generally agree with the following approach found in the",
"    <span class=\"nowrap\">",
"     ACCF/AHA",
"    </span>",
"    guidelines (and their focused updates) on",
"    <span class=\"nowrap\">",
"     UA/NSTEMI",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The creatinine clearance (CrCl) should be estimated in all patients and the doses of renally cleared medications adjusted. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=see_link\">",
"       \"Assessment of kidney function\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients receiving contrast media should be hydrated in advance. The contrast volume to CrCl ratio may be helpful in determining the maximal amount of contrast material should be given. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35498?source=see_link\">",
"       \"Prevention of contrast-induced nephropathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with mild (stage II) and moderate (stage III) CKD may benefit from an invasive strategy. It is uncertain whether patients with more advanced CKD benefit from this approach. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37434?source=see_link\">",
"       \"Overview of the management of chronic kidney disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     METHOD OF TREATMENT IN MULTIVESSEL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients found to have multivessel disease (including the culprit lesion) after coronary arteriography, there are four major therapeutic options:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medical therapy (generally for patients who cannot be revascularized)",
"     </li>",
"     <li>",
"      Culprit",
"      <span class=\"nowrap\">",
"       lesion/vessel",
"      </span>",
"      PCI only",
"     </li>",
"     <li>",
"      Multivessel PCI (including the culprit lesion)",
"     </li>",
"     <li>",
"      CABG",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following discussion applies to patients in whom revascularization will be undertaken.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Multivessel versus culprit only PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;In non-ST elevation patients with multivessel disease for whom PCI is chosen as the revascularization strategy, the operator must decide between culprit only or multivessel PCI. There have been no randomized trials comparing complete to incomplete revascularization (ICR) in these patients.",
"   </p>",
"   <p>",
"    The following studies provide some evidence to support a multivessel approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The safety and efficacy of multivessel stenting versus culprit-only stenting with bare metal stents was evaluated in a retrospective study of 1240 patients with NSTEMI [",
"      <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/50\">",
"       50",
"      </a>",
"      ]. Multivessel stenting was associated with a significant reduction in the composite end point of death, MI or revascularization during a mean follow-up of 2.3 years (hazard ratio 0.80, 95 % CI 0.64 - 0.99). However, the difference was entirely attributable to a lower revascularization rate. Safety end points did not differ between the two groups.",
"     </li>",
"     <li>",
"      In a substudy of the ACUITY trial (of patients with NSTEACS treated with an early invasive strategy who were randomly assigned to differing antithrombotic regimens), quantitative coronary angiography of the entire coronary tree was performed in 2954 individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/51\">",
"       51",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/2/5162?source=see_link&amp;anchor=H33#H33\">",
"       \"Anticoagulant therapy in non-ST elevation acute coronary syndromes\", section on 'Bivalirudin'",
"      </a>",
"      .).",
"      <br/>",
"      <br/>",
"      ICR was variably defined if any lesion with diameter stenosis cutoffs ranging from &ge;30, &ge;40, &ge;50, &ge;60, and &ge;70 percent remained after PCI. With these cutoffs, the prevalence of ICR was 75, 55, 37, 25, and 17 percent, respectively. The primary composite outcome (one-year rate of death, myocardial infarction, or ischemia-driven unplanned revascularization) was increased at all cutoffs compared individuals with complete revascularization. Using &ge;50 percent as the definition, ICR was associated with higher rates of the primary end point (23.4 versus 16.6 percent; hazard ratio [HR] 1.47, 95% CI 1.24-1.74), myocardial infarction (12.0 versus 6.2 percent; HR 1.50, 95% CI 1.18-1.89), and ischemia-driven unplanned revascularization (15.7 versus 10.2 percent; HR 1.58, 95% CI 1. 28-1.96), with a trend toward increased mortality (3.1 versus 2.2 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Until additional evidence is available, we agree with the approach advocated in the 2011 European Society of Cardiology guidelines for the management of ACS in patients presenting without ST-segment elevation, which suggests that decision between culprit lesion only or multivessel PCI should be made based on clinical status and disease severity. The use of adjunctive diagnostic technology, such as fractional flow reserve or intravascular ultrasound, may guide the decision [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     PCI versus CABG",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients for whom multivessel revascularization is deemed necessary, CABG is often preferred over PCI for the treatment of patients with left main or left main equivalent disease, or three or two vessel disease involving the left anterior descending artery in patients with a reduced left ventricular ejection fraction or treated diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/4,53\">",
"     4,53",
"    </a>",
"    ]. Among patients undergoing early revascularization in FRISC II, TACTICS-TIMI 18, and RITA 3, for example, CABG was performed in 33 to 42 percent of patients, most often for three vessel or left main disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/19,22,23\">",
"     19,22,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=see_link\">",
"     \"Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients who are angiographically eligible for either approach, CABG was compared to PCI in the AWESOME and ERACI II trials [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. A limitation to both trials is that they were performed before the availability of drug-eluting stents, which markedly reduce the rate of revascularization. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Drug-eluting stents'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The AWESOME trial consisted of 454 patients who had medically refractory UA or provocable ischemia after stabilization with medical therapy; the patients were eligible for both CABG and PCI, and were also at high risk for increased 30-day postoperative mortality after CABG (eg, age greater than 70, acute MI within the previous six days, and left ventricular ejection fraction less than 35 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/54,57\">",
"     54,57",
"    </a>",
"    ]. Patients with specific indications for CABG (&gt;50 percent left main stenosis or no dilatable vessels) were excluded.",
"   </p>",
"   <p>",
"    The patients were randomly assigned to undergo PCI (54 percent with stenting and 11 percent with a glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor) or CABG. The following results were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/54,57\">",
"     54,57",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PCI and CABG were associated with similar mortality rates in-hospital, and at 30 days (3 versus 5 percent), three years (18 versus 21 percent), and five years (25 versus 30 percent).",
"     </li>",
"     <li>",
"      At three years, survival free of UA or repeat revascularization was less with PCI (48 versus 61 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar results were noted in 1650 clinically eligible, but nonrandomized patients who were enrolled in the AWESOME registry [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ERACI II randomly assigned 450 patients with multivessel disease and an indication for revascularization (91 percent with UA) to PCI with stenting using bare metal stents or CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/56\">",
"     56",
"    </a>",
"    ]. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At 30 days, there was a significantly lower rate of major adverse events (death, MI, repeat revascularization, or stroke) with PCI (3.6 versus 12.3 percent with CABG). This difference was largely due to reductions in mortality and STEMI with PCI (0.9 versus 5.7 percent for both), a difference that was not seen in AWESOME.",
"     </li>",
"     <li>",
"      At a mean follow-up of 18 months, mortality remained significantly lower with PCI (3.1 versus 7.5 percent), but the excess deaths all occurred in the first 30 days. There was a significant increase in new revascularization procedures with PCI (17 versus 5 percent). These findings persisted out to five years [",
"      <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/58\">",
"       58",
"      </a>",
"      ]. The mortality rate was lower but no longer significant with PCI (7.2 versus 11.6 percent), but the rate of repeat revascularization remained significantly higher with PCI (28.5 versus 7.6 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The safety of multivessel PCI among patients with an acute MI (both non-ST and ST elevation) was also suggested in a retrospective study from the Mayo Clinic [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/59\">",
"     59",
"    </a>",
"    ]. Multivessel PCI (97 percent with stents) was not associated with an excess risk of mortality or the combined end point of death, myocardial infarction, CABG, or target vessel revascularization compared to single vessel PCI (both performed at mean of about two days after the MI).",
"   </p>",
"   <p>",
"    Patients with concomitant valvular disease are frequently cited as another subgroup that requires surgical intervention. While surgery for significant valve dysfunction may be necessary, performing PCI prior to valve surgery may be an appropriate alternative to a combined",
"    <span class=\"nowrap\">",
"     valve/CABG",
"    </span>",
"    operation. This was suggested by a study of initial PCI followed by valve surgery in 26 patients, most presenting with an ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/60\">",
"     60",
"    </a>",
"    ]. Operative mortality was significantly lower than that predicted by the algorithm of the Society of Thoracic Surgeons for a combined surgical procedure in this setting (3.8 versus 22 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     DRUG-ELUTING STENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-eluting stents are commonly used in patients with non-ST elevation ACS. The evidence to support their use (as opposed to bare metal stents) is limited but suggests that their safety profile and the benefit of a lower rate of target vessel revascularization are maintained in patients with ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43702?source=see_link\">",
"     \"Drug-eluting intracoronary stents: General principles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SPECIAL SITUATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three special situations in patients with non-ST elevation ACS merit comment: cardiogenic shock, recurrent ischemia, and chronic kidney disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Cardiogenic shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials assessing the efficacy of coronary arteriography and revascularization in the setting of NSTEMI and cardiogenic shock. Series of unselected patients with acute MI and cardiogenic shock have reported a lower mortality in those who undergo successful PCI compared to those with failed PCI, those not selected for coronary arteriography and PCI, and historical controls. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=see_link\">",
"     \"Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An international registry evaluated 251 patients with cardiogenic shock, 14 percent of whom had initial electrocardiographic findings suggestive of NSTEMI [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/63\">",
"     63",
"    </a>",
"    ]. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with an NSTEMI underwent cardiac catheterization significantly less often than those with initial ECG findings suggestive of an STEMI (29 versus 62 percent) and had a nonsignificant trend toward a higher mortality (77 versus 64 percent).",
"     </li>",
"     <li>",
"      Among patients with an NSTEMI, mortality was lower in those undergoing either PCI (50 percent) or CABG (33 percent) than in those who did not undergo revascularization (76 percent). However, patients selected for coronary arteriography who did not undergo revascularization had a similar mortality to those who underwent revascularization, suggesting that healthier patients may have been preferentially selected for catheterization.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The limited available data suggest that revascularization may reduce the mortality of cardiogenic shock in the setting of acute NSTEMI, similar to the data for STEMI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Recurrent ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early recurrent coronary ischemia after a non-ST elevation ACS can be silent (detected primarily by stress testing) or symptomatic. Patients with recurrent angina after acute MI are at high risk of reinfarction and death. As a result, coronary arteriography followed by revascularization is used extensively in this setting. There is a high rate of procedural success and a low rate of perioperative mortality or late recurrent MI or death.",
"   </p>",
"   <p>",
"    The best data on the efficacy of revascularization in patients with early post-MI angina comes from the DANAMI trial [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/64\">",
"     64",
"    </a>",
"    ]. However, the applicability of this trial to patients with non-ST elevation acute coronary syndromes is uncertain. Most patients in DANAMI had Q waves. Among the 24 percent who did not have Q waves, it was not reported whether these patients had or did not have ST elevation.",
"   </p>",
"   <p>",
"    In DANAMI, approximately 1000 patients treated with a fibrinolytic agent who had either spontaneous symptomatic angina or inducible post-MI ischemia on a predischarge exercise test were randomly assigned to conservative therapy or revascularization with angioplasty or bypass surgery; 56 percent had only silent ischemia. Patients in the revascularization arm were scheduled to undergo arteriography within two weeks of the exercise test, with PTCA without stenting performed if the anatomy was appropriate. For other patients with a correctable lesion, CABG was scheduled within five weeks of randomization. Among these patients, 53 percent underwent PTCA without stenting and 29 percent underwent CABG.",
"   </p>",
"   <p>",
"    At one, two, and four years, the primary end points (mortality, reinfarction, or admission for unstable angina) occurred significantly less frequently in the invasive group compared to those treated conservatively (15 versus 30 percent, 24 versus 37 percent, and 32 versus 44 percent, respectively). The benefit was due to reductions in reinfarction and admission for unstable angina since mortality after a median follow-up of 2.4 years was the same in both groups (3.6 versus 4.4 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of recurrent ischemia after a non-ST acute coronary syndrome is usually reperfusion with PCI. The",
"    <span class=\"nowrap\">",
"     ACCF/AHA",
"    </span>",
"    guidelines on unstable",
"    <span class=\"nowrap\">",
"     angina/non-ST",
"    </span>",
"    elevation MI (and their focused updates) considered recurrent ischemia a clear indication for an early invasive strategy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are two other settings in which recurrent ischemia can occur in these patients. The first is recurrent angina after PCI, which can represent stent thrombosis or incomplete revascularization and is an indication for urgent repeat PCI. The second is silent ischemia detected on stress testing performed before discharge in patients who have not been revascularized or within the first few weeks after discharge in those who have. The management of silent ischemia soon a non-ST elevation ACS is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4665?source=see_link&amp;anchor=H16#H16\">",
"     \"Silent myocardial ischemia: Prognosis and therapy\", section on 'Post-MI ischemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     TIMING OF DISCHARGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal duration of hospitalization for patients with non-ST elevation ACS who have been revascularized with PCI has not been defined. The employment of early angiography and revascularization has led to shorter hospitalizations, and the use of stenting and potent antiplatelet therapy in the periprocedural period has led to a reduction in recurrent ischemic events. On the other hand, antiplatelet and antithrombotic therapies are associated with an increased risk of major bleeding.",
"   </p>",
"   <p>",
"    The EASY trial evaluated the safety and feasibility of early discharge in 1005 moderate risk ACS patients (approximately 14 percent had stable angina pectoris) using a radial artery catheterization [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/65\">",
"     65",
"    </a>",
"    ]. Patients were randomly assigned to PCI with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    bolus and same day discharge or to a PCI with abciximab bolus followed by a 12 hour abciximab infusion and overnight hospitalization. Same-day discharge was significantly noninferior to overnight hospitalization in terms of the primary end point of death, MI, urgent revascularization, major bleeding, repeat hospitalization, severe thrombocytopenia, and access site complications at 30 days (20.4 versus 18.2 percent). Radial artery catheterization is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=see_link&amp;anchor=H23#H23\">",
"     \"Periprocedural complications of percutaneous coronary intervention\", section on 'Vascular complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/38/18020?source=see_link\">",
"       \"Patient information: Heart stents and angioplasty (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/16/40195?source=see_link\">",
"       \"Patient information: Heart attack (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/62/31717?source=see_link\">",
"       \"Patient information: Coronary artery bypass graft surgery (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following recommendations regarding early referral to the catheterization laboratory apply to the initial evaluation and management of patients with a non-ST elevation ACS. These patients should receive other therapeutic interventions shown to be of benefit in this setting. Comorbidities and patient preference need to be taken into account in the decision-making process. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=see_link\">",
"     \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The recommendations are generally in accord with those published by the American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACCF/AHA)",
"    </span>",
"    in their guidelines (and focused updates) on unstable angina and NSTEMI, by the",
"    <span class=\"nowrap\">",
"     ACC/AHA/Society",
"    </span>",
"    for Cardiac Angiography and Intervention (SCAI) in 2009 in the focused update on PCI, and in 2005 in the European Society of Cardiology task force report on PCI [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/3,4,66,67\">",
"     3,4,66,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple randomized controlled trials, two meta-analyses, and one large registry have confirmed that individual patients with non-ST elevation ACS are at widely varying risk for adverse events in both the short and long term. Early risk stratification is essential in order to identify those patients who may benefit from a more aggressive therapeutic approach. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Early risk assessment'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Immediate angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have a non-ST elevation ACS and one or more of the following characteristics are at extremely high risk of an adverse cardiovascular event in the short term:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemodynamic instability or cardiogenic shock",
"     </li>",
"     <li>",
"      Severe left ventricular dysfunction or heart failure",
"     </li>",
"     <li>",
"      Recurrent or persistent rest angina despite intensive medical therapy",
"     </li>",
"     <li>",
"      New or worsening mitral regurgitation or new ventricular septal defect",
"     </li>",
"     <li>",
"      Sustained ventricular arrhythmias",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We recommend that patients with any of these five characteristics be referred for immediate coronary arteriography and revascularization (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Indications for immediate angiography'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Early angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stable patients with one or more of the following characteristics are at high risk of an adverse event in the short term [",
"    <a class=\"abstract\" href=\"UTD.htm?29/1/29722/abstract/4,53\">",
"     4,53",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prior PCI within six months or prior CABG",
"     </li>",
"     <li>",
"      New or presumably new ST segment depression",
"     </li>",
"     <li>",
"      Elevated cardiac enzymes",
"     </li>",
"     <li>",
"      Recurrent angina or ischemia at rest or with low level activity despite intensive antiischemic therapy",
"     </li>",
"     <li>",
"      LVEF &lt;40 percent",
"     </li>",
"     <li>",
"      TIMI risk score greater than 2 (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?5/34/5665?source=see_link\">",
"       calculator 1",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We recommend that patients with any of these six characteristics be referred for an early intervention, as opposed to a conservative strategy (",
"    <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"     Grade 1A",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Patients who derive benefit'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Our current practice is to perform catheterization within 4 to 24 hours of admission. Stable patients at very high risk, such as those with a TIMI risk score of 5 or greater (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?5/34/5665?source=see_link\">",
"     calculator 1",
"    </a>",
"    ), may benefit from earlier intervention. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Timing of early intervention'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Conservative strategy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A minority of hospitalized patients with ACS are deemed to be at low risk (eg, TIMI risk score 0 to 2 and lacking the above features) and may be managed with a conservative approach, particularly if there is a patient preference to do so. Our practice is to perform stress testing before or within 48 hours of discharge.",
"   </p>",
"   <p>",
"    Patients in this category who subsequently develop high risk predictors or who manifest high risk findings on noninvasive stress testing should be referred for diagnostic coronary arteriography and possible revascularization.",
"   </p>",
"   <p>",
"    However, for most of these lower risk patients, we suggest an early invasive approach in an attempt to expedite care and to provide the patient with a definitive diagnosis (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ).",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/1\">",
"      Thygesen K, Alpert JS, White HD, Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J 2007; 28:2525.",
"     </a>",
"    </li>",
"    <li>",
"     Anderson J, Adams C, Antman E, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, American College or Physicians, Society for Academic Emergency Medicine, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2007; 50:e1 www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/3\">",
"      2012 Writing Committee Members, Jneid H, Anderson JL, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2012; 126:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/4\">",
"      Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 123:2022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/5\">",
"      Armstrong PW, Fu Y, Chang WC, et al. Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators. Circulation 1998; 98:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/6\">",
"      Liebson PR, Klein LW. The non-Q wave myocardial infarction revisited: 10 years later. Prog Cardiovasc Dis 1997; 39:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/7\">",
"      Haim M, Hod H, Reisin L, et al. Comparison of short- and long-term prognosis in patients with anterior wall versus inferior or lateral wall non-Q-wave acute myocardial infarction. Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT) Study Group. Am J Cardiol 1997; 79:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/8\">",
"      Goto K, Lansky AJ, Fahy M, et al. Predictors of outcomes in medically treated patients with acute coronary syndromes after angiographic triage: an Acute Catheterization And Urgent Intervention Triage Strategy (ACUITY) substudy. Circulation 2010; 121:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/9\">",
"      Morrow DA, Antman EM, Snapinn SM, et al. An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS. Eur Heart J 2002; 23:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/10\">",
"      Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA 2000; 284:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/11\">",
"      Januzzi JL Jr, Newby LK, Murphy SA, et al. Predicting a late positive serum troponin in initially troponin-negative patients with non-ST-elevation acute coronary syndrome: clinical predictors and validated risk score results from the TIMI IIIB and GUSTO IIA studies. Am Heart J 2006; 151:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/12\">",
"      Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. Circulation 1994; 89:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/13\">",
"      Anderson HV, Cannon CP, Stone PH, et al. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. J Am Coll Cardiol 1995; 26:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/14\">",
"      Jang IK, Gold HK, Ziskind AA, et al. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis. Circulation 1989; 79:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/15\">",
"      Mizuno K, Satomura K, Miyamoto A, et al. Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes. N Engl J Med 1992; 326:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/16\">",
"      Kerensky RA, Wade M, Deedwania P, et al. Revisiting the culprit lesion in non-Q-wave myocardial infarction. Results from the VANQWISH trial angiographic core laboratory. J Am Coll Cardiol 2002; 39:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/17\">",
"      Wong GC, Morrow DA, Murphy S, et al. Elevations in troponin T and I are associated with abnormal tissue level perfusion: a TACTICS-TIMI 18 substudy. Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction. Circulation 2002; 106:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/18\">",
"      Early effects of tissue-type plasminogen activator added to conventional therapy on the culprit coronary lesion in patients presenting with ischemic cardiac pain at rest. Results of the Thrombolysis in Myocardial Ischemia (TIMI IIIA) Trial. Circulation 1993; 87:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/19\">",
"      Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet 1999; 354:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/20\">",
"      Wallentin L, Lagerqvist B, Husted S, et al. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease. Lancet 2000; 356:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/21\">",
"      Lagerqvist B, Husted S, Kontny F, et al. A long-term perspective on the protective effects of an early invasive strategy in unstable coronary artery disease: two-year follow-up of the FRISC-II invasive study. J Am Coll Cardiol 2002; 40:1902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/22\">",
"      Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344:1879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/23\">",
"      Fox KA, Poole-Wilson PA, Henderson RA, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina. Lancet 2002; 360:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/24\">",
"      Spacek R, Widimsk&yacute; P, Straka Z, et al. Value of first day angiography/angioplasty in evolving Non-ST segment elevation myocardial infarction: an open multicenter randomized trial. The VINO Study. Eur Heart J 2002; 23:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/25\">",
"      Lagerqvist B, Husted S, Kontny F, et al. 5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study. Lancet 2006; 368:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/26\">",
"      Morrow DA, Cannon CP, Rifai N, et al. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA 2001; 286:2405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/27\">",
"      Fox KA, Poole-Wilson P, Clayton TC, et al. 5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial. Lancet 2005; 366:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/28\">",
"      Mehta SR, Cannon CP, Fox KA, et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA 2005; 293:2908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/29\">",
"      Bavry AA, Kumbhani DJ, Rassi AN, et al. Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials. J Am Coll Cardiol 2006; 48:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/30\">",
"      Boden WE, O'Rourke RA, Crawford MH, et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. N Engl J Med 1998; 338:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/31\">",
"      de Winter RJ, Windhausen F, Cornel JH, et al. Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med 2005; 353:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/32\">",
"      Hirsch A, Windhausen F, Tijssen JG, et al. Long-term outcome after an early invasive versus selective invasive treatment strategy in patients with non-ST-elevation acute coronary syndrome and elevated cardiac troponin T (the ICTUS trial): a follow-up study. Lancet 2007; 369:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/33\">",
"      Mehta SR, Granger CB, Boden WE, et al. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med 2009; 360:2165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/34\">",
"      Neumann FJ, Kastrati A, Pogatsa-Murray G, et al. Evaluation of prolonged antithrombotic pretreatment (\"cooling-off\" strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial. JAMA 2003; 290:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/35\">",
"      Riezebos RK, Ronner E, Ter Bals E, et al. Immediate versus deferred coronary angioplasty in non-ST-segment elevation acute coronary syndromes. Heart 2009; 95:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/36\">",
"      Montalescot G, Cayla G, Collet JP, et al. Immediate vs delayed intervention for acute coronary syndromes: a randomized clinical trial. JAMA 2009; 302:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/37\">",
"      Diderholm E, Andr&eacute;n B, Frostfeldt G, et al. The prognostic and therapeutic implications of increased troponin T levels and ST depression in unstable coronary artery disease: the FRISC II invasive troponin T electrocardiogram substudy. Am Heart J 2002; 143:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/38\">",
"      Kleiman NS, Lakkis N, Cannon CP, et al. Prospective analysis of creatine kinase muscle-brain fraction and comparison with troponin T to predict cardiac risk and benefit of an invasive strategy in patients with non-ST-elevation acute coronary syndromes. J Am Coll Cardiol 2002; 40:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/39\">",
"      Diderholm E, Andr&eacute;n B, Frostfeldt G, et al. ST depression in ECG at entry indicates severe coronary lesions and large benefits of an early invasive treatment strategy in unstable coronary artery disease; the FRISC II ECG substudy. The Fast Revascularisation during InStability in Coronary artery disease. Eur Heart J 2002; 23:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/40\">",
"      Holmvang L, Clemmensen P, Lindahl B, et al. Quantitative analysis of the admission electrocardiogram identifies patients with unstable coronary artery disease who benefit the most from early invasive treatment. J Am Coll Cardiol 2003; 41:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/41\">",
"      Solomon DH, Stone PH, Glynn RJ, et al. Use of risk stratification to identify patients with unstable angina likeliest to benefit from an invasive versus conservative management strategy. J Am Coll Cardiol 2001; 38:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/42\">",
"      Bach RG, Cannon CP, Weintraub WS, et al. The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes. Ann Intern Med 2004; 141:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/43\">",
"      Sabatine MS, Morrow DA, McCabe CH, et al. Combination of quantitative ST deviation and troponin elevation provides independent prognostic and therapeutic information in unstable angina and non-ST-elevation myocardial infarction. Am Heart J 2006; 151:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/44\">",
"      Ricciardi MJ, Wu E, Davidson CJ, et al. Visualization of discrete microinfarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation. Circulation 2001; 103:2780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/45\">",
"      Lindahl B, Diderholm E, Lagerqvist B, et al. Mechanisms behind the prognostic value of troponin T in unstable coronary artery disease: a FRISC II substudy. J Am Coll Cardiol 2001; 38:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/46\">",
"      Cannon CP, McCabe CH, Stone PH, et al. The electrocardiogram predicts one-year outcome of patients with unstable angina and non-Q wave myocardial infarction: results of the TIMI III Registry ECG Ancillary Study. Thrombolysis in Myocardial Ischemia. J Am Coll Cardiol 1997; 30:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/47\">",
"      Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. J Am Coll Cardiol 2011; 57:e215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/48\">",
"      Charytan DM, Wallentin L, Lagerqvist B, et al. Early angiography in patients with chronic kidney disease: a collaborative systematic review. Clin J Am Soc Nephrol 2009; 4:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/49\">",
"      Szummer K, Lundman P, Jacobson SH, et al. Influence of renal function on the effects of early revascularization in non-ST-elevation myocardial infarction: data from the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). Circulation 2009; 120:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/50\">",
"      Shishehbor MH, Lauer MS, Singh IM, et al. In unstable angina or non-ST-segment acute coronary syndrome, should patients with multivessel coronary artery disease undergo multivessel or culprit-only stenting? J Am Coll Cardiol 2007; 49:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/51\">",
"      Rosner GF, Kirtane AJ, Genereux P, et al. Impact of the presence and extent of incomplete angiographic revascularization after percutaneous coronary intervention in acute coronary syndromes: the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. Circulation 2012; 125:2613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/52\">",
"      Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32:2999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/53\">",
"      Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 2004; 110:e340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/54\">",
"      Morrison DA, Sethi G, Sacks J, et al. Percutaneous coronary intervention versus coronary artery bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass: a multicenter, randomized trial. Investigators of the Department of Veterans Affairs Cooperative Study #385, the Angina With Extremely Serious Operative Mortality Evaluation (AWESOME). J Am Coll Cardiol 2001; 38:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/55\">",
"      Morrison DA, Sethi G, Sacks J, et al. Percutaneous coronary intervention versus coronary bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass: The VA AWESOME multicenter registry: comparison with the randomized clinical trial. J Am Coll Cardiol 2002; 39:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/56\">",
"      Rodriguez A, Bernardi V, Navia J, et al. Argentine Randomized Study: Coronary Angioplasty with Stenting versus Coronary Bypass Surgery in patients with Multiple-Vessel Disease (ERACI II): 30-day and one-year follow-up results. ERACI II Investigators. J Am Coll Cardiol 2001; 37:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/57\">",
"      Stroupe KT, Morrison DA, Hlatky MA, et al. Cost-effectiveness of coronary artery bypass grafts versus percutaneous coronary intervention for revascularization of high-risk patients. Circulation 2006; 114:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/58\">",
"      Rodriguez AE, Baldi J, Fern&aacute;ndez Pereira C, et al. Five-year follow-up of the Argentine randomized trial of coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple vessel disease (ERACI II). J Am Coll Cardiol 2005; 46:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/59\">",
"      Chen LY, Lennon RJ, Grantham JA, et al. In-hospital and long-term outcomes of multivessel percutaneous coronary revascularization after acute myocardial infarction. Am J Cardiol 2005; 95:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/60\">",
"      Byrne JG, Leacche M, Unic D, et al. Staged initial percutaneous coronary intervention followed by valve surgery (\"hybrid approach\") for patients with complex coronary and valve disease. J Am Coll Cardiol 2005; 45:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/61\">",
"      Kandzari DE, Roe MT, Ohman EM, et al. Frequency, predictors, and outcomes of drug-eluting stent utilization in patients with high-risk non-ST-segment elevation acute coronary syndromes. Am J Cardiol 2005; 96:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/62\">",
"      Mauri L, Silbaugh TS, Garg P, et al. Drug-eluting or bare-metal stents for acute myocardial infarction. N Engl J Med 2008; 359:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/63\">",
"      Hochman JS, Boland J, Sleeper LA, et al. Current spectrum of cardiogenic shock and effect of early revascularization on mortality. Results of an International Registry. SHOCK Registry Investigators. Circulation 1995; 91:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/64\">",
"      Madsen JK, Grande P, Saunam&auml;ki K, et al. Danish multicenter randomized study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction (DANAMI). DANish trial in Acute Myocardial Infarction. Circulation 1997; 96:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/65\">",
"      Bertrand OF, De Larochelli&egrave;re R, Rod&eacute;s-Cabau J, et al. A randomized study comparing same-day home discharge and abciximab bolus only to overnight hospitalization and abciximab bolus and infusion after transradial coronary stent implantation. Circulation 2006; 114:2636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/66\">",
"      Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009; 54:2205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/1/29722/abstract/67\">",
"      Silber S, Albertsson P, Avil&eacute;s FF, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005; 26:804.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 46 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-210.101.131.232-F1D7113C53-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_1_29722=[""].join("\n");
var outline_f29_1_29722=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      UA and NSTEMI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Early invasive and early conservative strategies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      GENERAL ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Early risk assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - TIMI risk score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Indications for immediate angiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      BENEFIT AND TIMING OF EARLY INTERVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Trials showing benefit from early intervention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - FRISC II trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - TACTICS-TIMI 18 trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - RITA 3 trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Meta-analyses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Trials showing no benefit from early intervention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - ICTUS trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Timing of early intervention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Patients who derive benefit",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Patients with CKD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      METHOD OF TREATMENT IN MULTIVESSEL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Multivessel versus culprit only PCI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PCI versus CABG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      DRUG-ELUTING STENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SPECIAL SITUATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Cardiogenic shock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Recurrent ischemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      TIMING OF DISCHARGE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Immediate angiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Early angiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Conservative strategy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/46\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/46|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?5/34/5665?source=related_link\" title=\"calculator 1\">",
"      Calculator: Thrombolysis in Myocardial Infarction (TIMI) score for unstable angina or non ST elevation myocardial infarction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/2/5162?source=related_link\">",
"      Anticoagulant therapy in non-ST elevation acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/38/27240?source=related_link\">",
"      Bypass surgery versus percutaneous intervention in the management of stable angina pectoris: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=related_link\">",
"      Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/42/42665?source=related_link\">",
"      Complications of diagnostic cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=related_link\">",
"      Criteria for the diagnosis of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43702?source=related_link\">",
"      Drug-eluting intracoronary stents: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44361?source=related_link\">",
"      Epidemiology of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22421?source=related_link\">",
"      Fibrinolytic (thrombolytic) agents in unstable angina and acute non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15034?source=related_link\">",
"      Initial evaluation and management of suspected acute coronary syndrome in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39225?source=related_link\">",
"      Mechanical complications of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=related_link\">",
"      Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37434?source=related_link\">",
"      Overview of the management of chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/62/31717?source=related_link\">",
"      Patient information: Coronary artery bypass graft surgery (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/16/40195?source=related_link\">",
"      Patient information: Heart attack (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/38/18020?source=related_link\">",
"      Patient information: Heart stents and angioplasty (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=related_link\">",
"      Periprocedural complications of percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35498?source=related_link\">",
"      Prevention of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/37/35418?source=related_link\">",
"      Prognosis and treatment of cardiogenic shock complicating acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2746?source=related_link\">",
"      Risk stratification after unstable angina or non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4665?source=related_link\">",
"      Silent myocardial ischemia: Prognosis and therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29257?source=related_link\">",
"      Trials of conservative versus early invasive therapy in unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_1_29723="ADA recognition measures";
var content_f29_1_29723=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F51147&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F51147&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    American Diabetic Association provider recognition measures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Measure",
"       </td>",
"       <td class=\"subtitle1\">",
"        Frequency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HbA1c test (calculate proportion of patients with HbA1c value of less than 8 and 10 percent)",
"       </td>",
"       <td>",
"        At least once a year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Retinal examination",
"       </td>",
"       <td>",
"        At least once a year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Foot care evaluation",
"       </td>",
"       <td>",
"        At least once a year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blood pressure measurement (calculate proportion of patients with diastolic pressures of less than 90 mm Hg)",
"       </td>",
"       <td>",
"        At least twice a year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Measurement of urinary protein/microalbumineria",
"       </td>",
"       <td>",
"        Once a year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lipid profile evaluation",
"       </td>",
"       <td>",
"        Once a year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tobacco smoking status and counseling referral (document in chart)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Assessment of patient monitoring of blood glucose (obtained from patient survey)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patient satisfaction questions (obtained from patient survey)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_1_29723=[""].join("\n");
var outline_f29_1_29723=null;
var title_f29_1_29724="Diagnosis nodular masses II";
var content_f29_1_29724=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F82043&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F82043&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of nodular soft tissue masses-II",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Type of nodule",
"      </td>",
"      <td class=\"subtitle1\">",
"       Location",
"      </td>",
"      <td class=\"subtitle1\">",
"       Characteristic features",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\" colspan=\"3\">",
"       Inflammatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Nodular panniculitis (erythema induratum)",
"      </td>",
"      <td>",
"       Subcutaneous, lower limbs (calf), often bilateral",
"      </td>",
"      <td>",
"       Erythematous, warm, tender, may recur, may ulcerate",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Systemic nodular panniculitis (Weber-Christian disease)",
"      </td>",
"      <td>",
"       Multifocal widespread",
"      </td>",
"      <td>",
"       2 to 10 cm, painful, with late induration and deeply indented scars; often with fever, arthralgia, eosinophilia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Enzymatic panniculitis",
"      </td>",
"      <td>",
"       Any fatty tissue",
"      </td>",
"      <td>",
"       Erythematous, irregular, painful",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Lupus profundus",
"      </td>",
"      <td>",
"       Widespread in fatty tissues",
"      </td>",
"      <td>",
"       Scaly erythematous skin, often painful, may scar; other lupus features",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Erythema nodosum",
"      </td>",
"      <td>",
"       Bilateral forelegs, ankles",
"      </td>",
"      <td>",
"       Erythematous, may recur",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Polyarteritis nodosa",
"      </td>",
"      <td>",
"       Lower limbs, symmetrical",
"      </td>",
"      <td>",
"       Purpuric papules, occasionally urticarial, recur; fever, hypertension, mononeuritis multiplex",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\" colspan=\"3\">",
"       Infections",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Atypical mycobacteria",
"      </td>",
"      <td>",
"       Extremities, hands",
"      </td>",
"      <td>",
"       Localized group of papules or erythema nodosa-like",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sporotrichosis",
"      </td>",
"      <td>",
"       Face, extremities",
"      </td>",
"      <td>",
"       Ulcerating red papule",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Treponemal",
"      </td>",
"      <td>",
"       Digits, face, nipples, extremities",
"      </td>",
"      <td>",
"       Ulcerating papules with regional lymphadenopathy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Meningococcus",
"      </td>",
"      <td>",
"       Multifocal widespread",
"      </td>",
"      <td>",
"       Petechial, purpuric, necrotic centers",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Gonococcus",
"      </td>",
"      <td>",
"       Extremities, fingers, toes",
"      </td>",
"      <td>",
"       Painful papules, pustules, bullae on erythematous base",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Hepatitis associated vasculitis",
"      </td>",
"      <td>",
"       Lower limbs, symmetrical",
"      </td>",
"      <td>",
"       Purpuric papules, occasionally urticarial, recur",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_1_29724=[""].join("\n");
var outline_f29_1_29724=null;
var title_f29_1_29725="Contents: Minimally invasive surgery";
var content_f29_1_29725=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?5/48/5902\">",
"       General Surgery",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Minimally invasive surgery",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Minimally invasive surgery",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/1/31770\">",
"           Abdominal access techniques used in laparoscopic surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/39/15992\">",
"           Diagnostic staging laparoscopy: General principles for staging primary digestive malignancies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/40/14984\">",
"           Devices for dissection and hemostasis in laparoscopic surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/22/25954\">",
"           Patient information: Minimally invasive surgery (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-B3E579AAF2-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f29_1_29725=[""].join("\n");
var outline_f29_1_29725=null;
var title_f29_1_29726="Tibiotalar arthritis in HH";
var content_f29_1_29726=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F51733&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F51733&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hemochromatosis of the ankle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 222px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plain radiograph of the ankle in a 45-year-old man with hemochromatosis shows marked destruction of the tibiotalar joint space, with loss of joint space and erosions of adjacent bone surfaces (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_1_29726=[""].join("\n");
var outline_f29_1_29726=null;
var title_f29_1_29727="Biclonal gammopathy on SPEP";
var content_f29_1_29727=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F54186&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F54186&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Biclonal gammopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 334px; height: 404px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel B: A biclonal pattern, with two small, discrete gamma bands, is seen on serum protein electrophoresis on agarose gel (anode on left). Panel A: Densitometer tracing of these findings shows the two protein peaks with gamma mobility.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_1_29727=[""].join("\n");
var outline_f29_1_29727=null;
